Hepcidin analogues and uses thereof

ABSTRACT

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No.14/775,469, filed Sep. 11, 2015; which is a U.S. National PhaseApplication of International Patent Application No. PCT/US2014/030352,filed Mar. 17, 2014; which claims the benefit under 35 U.S.C. § 119(e)of U.S. Provisional Application No. 61/800,048, filed on Mar. 15, 2013,and U.S. Provisional Application No. 61/800,284, filed on Mar.15, 2013,each of which is incorporated by reference herein in its entirety.

STATEMENT REGARDING SEQUENCE LISTING

The Sequence Listing associated with this application is provided intext format in lieu of a paper copy, and is hereby incorporated byreference into the specification. The name of the text file containingthe Sequence Listing is PRTH_001_02US_ST25.txt. The text file is 126 KB,was created on Sep. 28, 2017, and is being submitted electronically viaEFS-Web.

FIELD OF THE INVENTION

The present invention relates, inter alia, to certain hepcidin peptideanalogues, including peptides and dimers thereof, as well ascompositions comprising the peptides and peptide dimers, and to the useof the peptides and peptide dimers in the treatment and/or prevention ofa variety of diseases, conditions or disorders, including treatmentand/or prevention of iron overload diseases including hereditaryhemochromatosis, iron-loading anemias, and other conditions anddisorders described herein.

BACKGROUND

Hepcidin (also referred to as LEAP-1), a peptide hormone produced by theliver, is a regulator of iron homeostasis in humans and other mammals.Hepcidin acts by binding to its receptor, the iron export channelferroportin, causing its internalization and degradation. Human hepcidinis a 25-amino acid peptide (Hep25). See Krause et al. (2000) FEBS Lett480:147-150, and Park et al. (2001) J Biol Chem 276:7806-7810. Thestructure of the bioactive 25-amino acid form of hepcidin is a simplehairpin with 8 cysteines that form 4 disulfide bonds as described byJordan et al. J Biol Chem 284:24155-67. The N terminal region isrequired for iron-regulatory function, and deletion of 5 N-terminalamino acid residues results in a loss of iron-regulatory function. SeeNemeth et al. (2006) Blood 107:328-33.

Abnormal hepcidin activity is associated with iron overload diseases,including hereditary hemochromatosis (HH) and iron-loading anemias.Hereditary hemochromatosis is a genetic iron overload disease that ismainly caused by hepcidin deficiency, or in some cases by hepcidinresistance. This allows excessive absorption of iron from the diet anddevelopment of iron overload. Clinical manifestations of HH may includeliver disease (e.g., hepatic cirrhosis and hepatocellular carcinoma),diabetes, and heart failure. Currently, the only treatment for HH isregular phlebotomy, which is very burdensome for the patients.Iron-loading anemias are hereditary anemias with ineffectiveerythropoiesis such as β-thalassemia, which are accompanied by severeiron overload. Complications from iron overload are the main cause ofmorbidity and mortality for these patients. Hepcidin deficiency is themain cause of iron overload in non-transfused patients, and contributesto iron overload in transfused patients. The current treatment for ironoverload in these patients is iron chelation which is very burdensome,sometimes ineffective, and accompanied by frequent side effects.

Hepcidin has a number of limitations which restrict its use as a drug,including a difficult synthesis process due in part to aggregation andprecipitation of the protein during folding, which in turn leads to highcost of goods. What are needed in the art are compounds having hepcidinactivity and also possessing other beneficial physical properties suchas improved solubility, stability, and/or potency, so that hepcidin-likebiologics might be produced affordably, and used to treathepcidin-related diseases and disorders such as, e.g., those describedherein.

The present invention addresses such needs, providing novel peptideanalogues, and dimers thereof, having hepcidin activity and also havingother beneficial properties making the peptides of the present inventionsuitable alternatives to hepcidin.

BRIEF SUMMARY OF THE INVENTION

The present invention generally relates to peptides exhibiting hepcidinactivity and methods of using the same.

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of, the following structural formula I:

R¹—X—Y—R²   (I) (SEQ ID NO:12)

-   or a pharmaceutically acceptable salt or solvate thereof, wherein-   R¹ is hydrogen, an C1-C6 alkyl, C6-C12 aryl, C6-C12 aryl C1-C6    alkyl, C1-C20 alkanoyl (e.g. methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g. PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R² is —NH₂ or —OH;-   X is a peptide sequence having the formula (Ia)

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia) (SEQ ID NO:1)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Lys, Ala, or D-His;-   X4 is Phe, Ala, Dpa, bhPhe, of D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   Y is absent or Y is a peptide having the formula (IIa)

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15   (IIa) (SEQ ID NO:5)

-   wherein-   Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent;-   Y2 is Pro, Ala, Cys, Gly or absent;-   Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent;-   Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent;-   Y5 is Lys, Met, Arg, Ala or absent;-   Y6 is Gly, Ser, Lys, Ile, Arg, Ala, Pro, Val or absent;-   Y7 is Trp, Lys, Gly, Ala Ile, Val or absent;-   Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or    absent;-   Y9 is Cys, Tyr or absent;-   Y10 is Met, Lys, Arg, Tyr or absent;-   Y11 is Arg, Met, Cys, Lys or absent;-   Y12 is Arg, Lys, Ala or absent;-   Y13 is Arg, Cys, Lys, Val or absent;-   Y14 is Arg, Lys, Pro, Cys, Thr or absent; and-   Y15 is Thr, Arg or absent;-   wherein if Y is absent from the peptide of formula (I), X7 is Ile;    and-   wherein said compound of formula (I) is optionally PEGylated on R¹,    X, or Y.

In some embodiments, the compound of formula (I) comprises two or morecysteine residues, wherein at least two of said cysteine residues arelinked via a disulfide bond.

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of the following structural formula I′:

R¹′—X′—Y′—R²′  (I′) (SEQ ID NO:21)

-   or a pharmaceutically acceptable salt or solvate thereof,-   wherein-   R¹′ is hydrogen, an C₁-C₆ alkyl, C₆-C₁₂ aryl, C₆-C₁₂ aryl C₁-C₆    alkyl, C₁-C₂₀ alkanoyl (e.g. methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g. PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R²′ is —NH₂ or —OH;

X′ is a peptide sequence having the formula Ia′

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia′) (SEQ ID NO:13)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Ala, D-His or Lys;-   X4 is Phe, Ala, Dpa, bhPhe or D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   and provided that if Y′ is absent, X7 is Ile;

Y′ is a peptide having the formula IIa′

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15   (IIa′) (SEQ IDNO:16)

-   wherein-   Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent;-   Y2 is Pro, Ala, Cys, Gly or absent;-   Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent;-   Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent;-   Y5 is Lys, Met, Arg, Ala or absent;-   Y6 is Gly, Ser, Lys, Ile, Ala, Pro, Val or absent;-   Y7 is Trp, Lys, Gly, Ala, Ile, Val or absent;-   Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or    absent;-   Y9 is Cys, Tyr or absent;-   Y10 is Met, Lys, Arg, Tyr or absent;-   Y11 is Arg, Met, Cys, Lys or absent;-   Y12 is Arg, Lys, Ala or absent;-   Y13 is Arg, Cys, Lys, Val or absent;-   Y14 is Arg, Lys, Pro, Cys, Thr or absent; and-   Y15 is Thr, Arg or absent;-   wherein said compound of formula I′ is optionally PEGylated on R¹′,    X′, or Y′; and-   wherein when said compound of formula I′ comprises two or more    cysteine residues, at least two of said cysteine residues being    linked via a disulfide bond.

In some embodiments, the compound of formula I′ comprises an R¹′ moietythat is hydrogen, isovaleric acid, isobutyric acid, or acetyl.

In some embodiments, the compound of formula I′ comprises an X′ peptideof formula Ia′ as described herein, wherein

-   X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;-   X2 is Thr, Ala, or D-Thr;-   X3 is His, Lys, D-His or Lys;-   X4 is Phe, Ala, Dpa or D-Phe;-   X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;-   X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;-   X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;-   X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;-   X9 is Phe or bhPhe; and-   X10 is Lys, Phe or absent.

In some embodiments, the compound of formula I′ comprises an X′ peptideof formula Ib′:

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib′)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments, the compound of formula I′ comprises an X′ peptideof formula Ic′:

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic′)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X8 is Ile Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments, the compound of formula I′ comprises a Y′ peptideof formula IIb′.

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10   (IIb′)

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp or Ala;-   Y8 is Val, Thr, Ala or Glu; and-   Y10 is Met, Lys or absent.

In some embodiments, the compound of formula I′ comprises a Y′ peptideof formula IIc′.

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10   (IIc′)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro or Gly;-   Y3 is Arg or Lys;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In some embodiments, the compound of formula I′ comprises a Y′ peptideof formula IId′:

Cys-Y3-Y4-Arg-Y6-Y7-Y8-Cys-Y10-Y11-Y12-Y13-Y14-Y15   (IId′)

-   wherein-   Y1 is Val or Ala or absent;-   Y3 is Gly, Pro or absent;-   Y4 is His, Trp or Tyr; Y6 is Ser, Gly or Pro;-   Y7 is Ile, Gly or Lys;-   Y8 is Gly, Met or absent;-   Y10 is Tyr or Cys;-   Y11 is Arg, Lys, Met or Ala;-   Y12 is Arg or Ala;-   Y13 is Cys or Val or absent;-   Y14 is Cys, Lys, Pro, Arg, Thr or absent; and-   Y15 is Arg, Thr or absent.

In some embodiments, the compound of formula I′ comprises a Y′ peptideof formula IIe′:

Val-Cys-Y3-His-Arg-Y6-Y7-Y8-Cys-Tyr-Arg-Y12-Y13-Y14-Y15   (IIe′)

-   wherein-   Y3 is Gly or absent;-   Y6 is Ser or Pro;-   Y7 is Ile or Lys;-   Y8 is Gly or absent;-   Y12 is Arg or Ala;-   Y13 is Cys or Val or absent;-   Y14 is Cys, Arg, Thr or absent; and-   Y15 is Arg or absent.

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of the following structural formula I″:

R¹″—X″—Y″—R²″  (I″) (SEQ ID NO:27)

-   or a pharmaceutically acceptable salt or solvate thereof, wherein-   R¹″ is hydrogen, an C₁-C₆ alkyl, C₆-C₁₂ aryl, C₆-C₁₂ aryl C₁-C₆    alkyl, C₁-C₂₀ alkanoyl (e.g. methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g. PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R²″ is —NH₂ or —OH;-   X″ is a peptide sequence having the formula Ia″

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia″) (SEQ ID NO:22)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Ala, D-His or Lys;-   X4 is Phe, Ala, Dpa, bhPhe or D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   and provided that if Y″ is absent, X7 is Ile.

In some embodiments, the compound of formula I″ is PEGylated on R¹″, X″,or Y″.

In some embodiments, the compound of formula I″ comprises two or morecysteine residues, at least two of said cysteine residues being linkedvia a disulfide bond.

In some embodiments, the compound of formula I″ comprises an R¹″ that ishydrogen, isovaleric acid, iso-butyric acid or acetyl.

In some embodiments, the compound of formula I″ comprises an X″ peptideaccording to formula Ia″, disclosed herein,

-   wherein-   X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;-   X2 is Thr, Ala, or D-Thr;-   X3 is His, Lys, D-His or Lys;-   X4 is Phe, Ala, or Dpa;-   X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;-   X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;-   X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;-   X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;-   X9 is Phe or bhPhe; and-   X10 is Lys or absent.

In some embodiments, the compound of formula I″ comprises an X″ peptideof formula Ib″:

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib″)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys, Phe or absent.

In some embodiments, the compound of formula I″ comprises an X″ peptideof formula Ic″:

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic″)

wherein

-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments, the compound of formula I″ comprises a Y″ peptideof formula IIa″:

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10   (IIa″) (SEQ ID NO:25)

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp, Ala or absent;-   Y8 is Val, Thr, Lys, Ala, Glu or absent; and-   Y10 is Met, Lys or absent.

In some embodiments, the compound of formula I″ comprises a Y″ peptideof formula IIb″:

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10   (IIb″)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro, Gly;-   Y3 is Arg, Lys;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In related embodiments, the present invention includes dimers, e.g.,homodimers, of any of the peptides of the present invention.

In some embodiments, the peptides or dimers of the present inventionexhibit hepcidin activity. In some embodiments, the peptides or dimersbind ferroportin, e.g., human ferroportin.

In some embodiments, the present invention provides methods of binding aferroportin or inducing ferroportin internalization and degradationwhich comprise contacting the ferroportin with at least one peptide,dimer or composition as disclosed herein.

In some embodiments, the present invention provides compositions andmedicaments comprising at least one peptide or dimer as disclosedherein.

In some embodiments, the present invention provides a method ofmanufacturing medicaments comprising at least one peptide or dimer asdisclosed herein for the treatment of diseases of iron metabolism, suchas iron overload diseases.

Also provided are methods of treating a disease of iron metabolism in asubject, such as a mammalian subject, e.g., a human subject, comprisingadministering at least one peptide, dimer or composition as disclosedherein to the subject. In some embodiments, the peptide or dimer isadministered in a therapeutically effective amount. In some embodiments,the disease of iron metabolism is an iron overload disease.

In some embodiments, the present invention provides a method ofmanufacturing a peptide or peptide dimer of the present inventionsynthetically. In some embodiments, the present invention provides amethod of manufacturing a peptide or peptide dimer of the presentinvention recombinantly.

In some embodiments, the present invention provides a pharmaceuticalcomposition comprising a peptide analogue (e.g., a peptide or dimer ofthe present invention), or pharmaceutically acceptable salt or solvatethereof, as described herein, in combination with one or more peptideanalogue (e.g., a peptide or dimer of the present invention) orpharmaceutically acceptable salt or solvate thereof, as described hereintogether with a pharmaceutically acceptable carrier, excipient orvehicle.

In some embodiments, the invention provides a process for manufacturinga compound or a pharmaceutical composition as disclosed herein.

In some embodiments, the invention provides a device comprising at leastone peptide analogue (e.g., a peptide or dimer of the presentinvention), or pharmaceutically acceptable salt or solvate thereof fordelivery of the peptide analogue to a subject.

In some embodiments, the present invention provides kits comprising atleast one peptide, dimer, or composition as disclosed herein packagedtogether with a reagent, a device, instructional material, or acombination thereof.

In some embodiments, the present invention provides complexes whichcomprise at least one peptide or dimer as disclosed herein bound to aferroportin, e.g., a human ferroportin, or an antibody, such as anantibody which specifically binds a peptide as disclosed herein, Hep25,or a combination thereof.

Both the foregoing general description and the following detaileddescription are exemplary and explanatory only and are intended toprovide further explanation of the invention as claimed. Theaccompanying drawings are included to provide a further understanding ofthe invention and are incorporated in and constitute part of thisspecification, illustrate several embodiments of the invention, andtogether with the description serve to explain the principles of theinvention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the results of an in vitro activity assay measuring theinduction of degradation of the human ferroportin protein. Presented aredose response curves for Compound No. 1 as compared to Hepcidin and theMini-Hepcidin control.

FIG. 2 shows time dependent changes in serum iron following animalexposure to vehicle, Compound No. 2 and reference compound RIMini-Hepcidin. The responses are normalized to the initial (t=0) levels.

FIG. 3 shows relative decrease of serum iron relative to vehicle controlmeasured with Compound No. 2 as well as the reference compoundRI-Mini-Hepcidin at timepoints 0, 30, 60, 120, 240 and 360 minutes. 100%represents the measured average level of serum iron in the vehicletreated animals.

FIG. 4 shows the in vivo serum iron reducing abilities of selectedpeptides of the present invention and Hepcidin.

FIG. 5 shows a dose response of the in vivo serum iron reducingabilities of selected peptides of the present invention and Hepcidin.

FIG. 6 shows the PK/PD effects for the in vivo serum iron reducingabilities of selected peptides of the present invention and Hepcidin.For Hepcidin and the 300 nmol/kg treatment with compound #181, only onetimepoint was taken at t=120 min. The Hepcidin response is not clearlyvisible on this graph, as it overlapped with the Cmpd #181 1000 nmol/kgplot at the t-120 min point. The single data point for compound #181 300nmol/kg is located directly above the Hepcidin point.

FIG. 7 shows selected examples of linkers that were used to dimerize thepeptides.

DETAILED DESCRIPTION OF THE INVENTION

Unless otherwise defined herein, scientific and technical terms used inthis application shall have the meanings that are commonly understood bythose of ordinary skill in the art. Generally, nomenclature used inconnection with, and techniques of, chemistry, molecular biology, celland cancer biology, immunology, microbiology, pharmacology, and proteinand nucleic acid chemistry, described herein, are those well-known andcommonly used in the art.

All publications, patents and published patent applications referred toin this application are specifically incorporated by reference herein.In case of conflict, the present specification, including its specificdefinitions, will control.

Each embodiment of the invention described herein may be taken alone orin combination with one or more other embodiments of the invention.

Definitions

Throughout this specification, the word “comprise” or variations such as“comprises” or “comprising” will be understood to imply the inclusion ofa stated integer (or components) or group of integers (or components),but not the exclusion of any other integer (or components) or group ofintegers (or components).

The singular forms “a,” “an,” and “the” include the plurals unless thecontext clearly dictates otherwise.

The term “including” is used to mean “including but not limited to.”“Including” and “including but not limited to” are used interchangeably.

The terms “patient,” “subject,” and “individual” may be usedinterchangeably and refer to either a human or a non-human animal. Theseterms include mammals such as humans, primates, livestock animals (e.g.,bovines, porcines), companion animals (e.g., canines, felines) androdents (e.g., mice and rats).

The term formula (I), is used herein interchangeably with the termformula I (i.e., without the parentheses). The term formula (I′), isused herein interchangeably with the term formula I′ (i.e., without theparentheses). The term formula (I″), is used herein interchangeably withthe term formula I″ (i.e., without the parentheses).

The recitations “sequence identity”, “percent identity”, “percenthomology”, or, for example, comprising a “sequence 50% identical to,” asused herein, refer to the extent that sequences are identical on anucleotide-by-nucleotide basis or an amino acid-by-amino acid basis overa window of comparison. Thus, a “percentage of sequence identity” may becalculated by comparing two optimally aligned sequences over the windowof comparison, determining the number of positions at which theidentical nucleic acid base (e.g., A, T, C, G, I) or the identical aminoacid residue (e.g., Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr,Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in bothsequences to yield the number of matched positions, dividing the numberof matched positions by the total number of positions in the window ofcomparison (i.e., the window size), and multiplying the result by 100 toyield the percentage of sequence identity.

Calculations of sequence similarity or sequence identity betweensequences (the terms are used interchangeably herein) can be performedas follows. To determine the percent identity of two amino acidsequences, or of two nucleic acid sequences, the sequences can bealigned for optimal comparison purposes (e.g., gaps can be introduced inone or both of a first and a second amino acid or nucleic acid sequencefor optimal alignment and non-homologous sequences can be disregardedfor comparison purposes). In certain embodiments, the length of areference sequence aligned for comparison purposes is at least 30%,preferably at least 40%, more preferably at least 50%, 60%, and evenmore preferably at least 70%, 80%, 90%, 100% of the length of thereference sequence. The amino acid residues or nucleotides atcorresponding amino acid positions or nucleotide positions are thencompared. When a position in the first sequence is occupied by the sameamino acid residue or nucleotide as the corresponding position in thesecond sequence, then the molecules are identical at that position.

The percent identity between the two sequences is a function of thenumber of identical positions shared by the sequences, taking intoaccount the number of gaps, and the length of each gap, which need to beintroduced for optimal alignment of the two sequences.

The comparison of sequences and determination of percent identitybetween two sequences can be accomplished using a mathematicalalgorithm. In some embodiments, the percent identity between two aminoacid sequences is determined using the Needleman and Wunsch, (1970, J.Mol. Biol. 48: 444-453) algorithm which has been incorporated into the

GAP program in the GCG software package, using either a Blossum 62matrix or a PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or4 and a length weight of 1, 2, 3, 4, 5, or 6. In yet another preferredembodiment, the percent identity between two nucleotide sequences isdetermined using the GAP program in the GCG software package, using anNWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80 and alength weight of 1, 2, 3, 4, 5, or 6. Another exemplary set ofparameters includes a Blossum 62 scoring matrix with a gap penalty of12, a gap extend penalty of 4, and a frameshift gap penalty of 5. Thepercent identity between two amino acid or nucleotide sequences can alsobe determined using the algorithm of E. Meyers and W. Miller (1989,Cabios, 4: 11-17) which has been incorporated into the ALIGN program(version 2.0), using a PAM120 weight residue table, a gap length penaltyof 12 and a gap penalty of 4.

The peptide sequences described herein can be used as a “query sequence”to perform a search against public databases to, for example, identifyother family members or related sequences. Such searches can beperformed using the NBLAST and XBLAST programs (version 2.0) ofAltschul, et al., (1990, J. Mol. Biol, 215: 403-10). BLAST nucleotidesearches can be performed with the NBLAST program, score=100,wordlength=12 to obtain nucleotide sequences homologous to nucleic acidmolecules of the invention. BLAST protein searches can be performed withthe XBLAST program, score=50, wordlength=3 to obtain amino acidsequences homologous to protein molecules of the invention. To obtaingapped alignments for comparison purposes, Gapped BLAST can be utilizedas described in Altschul et al. (Nucleic Acids Res. 25:3389-3402, 1997).When utilizing BLAST and Gapped BLAST programs, the default parametersof the respective programs (e.g., XBLAST and NBLAST) can be used.

As used herein, the term “pharmaceutically acceptable salt” is intendedto indicate a salt which is not harmful to a patient or subject to whichthe salt in question is administered. It may suitably be a salt chosen,e.g., among acid addition salts and basic salts. Examples of acidaddition salts include chloride salts, citrate salts and acetate salts.Examples of basic salts include salts where the cation is selected amongalkali metal cations, such as sodium or potassium ions, alkaline earthmetal cations, such as calcium or magnesium ions, as well as substitutedammonium ions, such as ions of the type N(R1)(R2)(R3)(R4)+, where R1,R2, R3 and R4 independently will typically designate hydrogen,optionally substituted C1-6-alkyl or optionally substitutedC2-6-alkenyl. Examples of relevant C1-6-alkyl groups include methyl,ethyl, 1-propyl and 2-propyl groups. Examples of C2-6-alkenyl groups ofpossible relevance include ethenyl, 1-propenyl and 2-propenyl. Otherexamples of pharmaceutically acceptable salts are described in“Remington's Pharmaceutical Sciences”, 17th edition, Alfonso R. Gennaro(Ed.), Mark Publishing Company, Easton, Pa., USA, 1985 (and more recenteditions thereof), in the “Encyclopaedia of Pharmaceutical Technology”,3rd edition, James Swarbrick (Ed.), Informa Healthcare USA (Inc.), NY,USA, 2007, and in J. Pharm. Sci. 66: 2 (1977). Also, for a review onsuitable salts, see Handbook of Pharmaceutical Salts: Properties,Selection, and Use by Stahl and Wermuth (Wiley-VCH, 2002). Othersuitable base salts are formed from bases which form non-toxic salts.Representative examples include the aluminum, arginine, benzathine,calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium,meglumine, olamine, potassium, sodium, tromethamine, and zinc salts.Hemisalts of acids and bases may also be formed, e.g., hemisulphate andhemicalcium salts. Compositions to be used in the invention suitable forparenteral administration may comprise sterile aqueous solutions and/orsuspensions of the pharmaceutically active ingredients preferably madeisotonic with the blood of the recipient, generally using sodiumchloride, glycerin, glucose, mannitol, sorbitol, and the like. Organicacids suitable for forming pharmaceutically acceptable acid additionsalts include, by way of example and not limitation, acetic acid,trifluoroacetic acid, propionic acid, hexanoic acid,cyclopentanepropionic acid, glycolic acid, oxalic acid, pyruvic acid,lactic acid, malonic acid, succinic acid, malic acid, maleic acid,fumaric acid, tartaric acid, citric acid, palmitic acid, benzoic acid,3-(4-hydroxybenzoyl) benzoic acid, cinnamic acid, mandelic acid,alkylsulfonic acids (e.g., methanesulfonic acid, ethanesulfonic acid,1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, etc.),arylsulfonic acids (e.g., benzenesulfonic acid, 4-chlorobenzenesulfonicacid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid,camphorsulfonic acid, etc.),4-methylbicyclo(2.2.2)-oct-2-ene-1-carboxylic acid, glucoheptonic acid,3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid,lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoicacid, salicylic acid, stearic acid, muconic acid, and the like.

The term “solvate” in the context of the present invention refers to acomplex of defined stoichiometry formed between a solute (in casu, apeptide analogue or pharmaceutically acceptable salt thereof accordingto the invention) and a solvent. The solvent in this connection may, forexample, be water, ethanol or another pharmaceutically acceptable,typically small-molecular organic species, such as, but not limited to,acetic acid or lactic acid. When the solvent in question is water, sucha solvate is normally referred to as a hydrate.

The term “agonist” as employed in the context of the invention refers toa substance (ligand) that causes internalization of the ferroportinprotein.

As used herein, a “disease of iron metabolism” includes diseases whereaberrant iron metabolism directly causes the disease, or where ironblood levels are dysregulated causing disease, or where irondysregulation is a consequence of another disease, or where diseases canbe treated by modulating iron levels, and the like. More specifically, adisease of iron metabolism according to this disclosure includes ironoverload diseases, iron deficiency disorders, disorders of ironbiodistribution, other disorders of iron metabolism and other disorderspotentially related to iron metabolism, etc. Diseases of iron metabolisminclude hemochromatosis, HFE mutation hemochromatosis, ferroportinmutation hemochromatosis, transferrin receptor 2 mutationhemochromatosis, hemojuvelin mutation hemochromatosis, hepcidin mutationhemochromatosis, juvenile hemochromatosis, neonatal hemochromatosis,hepcidin deficiency, transfusional iron overload, thalassemia,thalassemia intermedia, alpha thalassemia, sideroblastic anemia,porphyria, porphyria cutanea tarda, African iron overload,hyperferritinemia, ceruloplasmin deficiency, atransferrinemia,congenital dyserythropoietic anemia, anemia of chronic disease, anemiaof inflammation, anemia of infection, hypochromic microcytic anemia,iron-deficiency anemia, iron-refractory iron deficiency anemia, anemiaof chronic kidney disease, erythropoietin resistance, iron deficiency ofobesity, other anemias, benign or malignant tumors that overproducehepcidin or induce its overproduction, conditions with hepcidin excess,Friedreich ataxia, gracile syndrome, Hallervorden-Spatz disease,Wilson's disease, pulmonary hemosiderosis, hepatocellular carcinoma,cancer, hepatitis, cirrhosis of liver, pica, chronic renal failure,insulin resistance, diabetes, atherosclerosis, neurodegenerativedisorders, multiple sclerosis, Parkinson's disease, Huntington'sdisease, and Alzheimer's disease.

In some embodiments, the disease and disorders are related to ironoverload diseases such as iron hemochromatosis, HFE mutationhemochromatosis, ferroportin mutation hemochromatosis, transferrinreceptor 2 mutation hemochromatosis, hemojuvelin mutationhemochromatosis, hepcidin mutation hemochromatosis, juvenilehemochromatosis, neonatal hemochromatosis, hepcidin deficiency,transfusional iron overload, thalassemia, thalassemia intermedia, alphathalassemia.

In some embodiments, the peptides of the invention are used to treatdiseases and disorders that are not typically identified as being ironrelated. For example, hepcidin is highly expressed in the murinepancreas suggesting that diabetes (Type I or Type II), insulinresistance, glucose intolerance and other disorders may be amelioratedby treating underlying iron metabolism disorders. See Ilyin, G. et al.(2003) FEBS Lett. 542 22-26, which is herein incorporated by reference.As such, peptides of the invention may be used to treat these diseasesand conditions. Those skilled in the art are readily able to determinewhether a given disease can be treated with a peptide according to thepresent invention using methods known in the art, including the assaysof WO 2004092405, which is herein incorporated by reference, and assayswhich monitor hepcidin, hemojuvelin, or iron levels and expression,which are known in the art such as those described in U.S. Pat. No.7,534,764, which is herein incorporated by reference.

In certain embodiments of the present invention, the diseases of ironmetabolism are iron overload diseases, which include hereditaryhemochromatosis, iron-loading anemias, alcoholic liver diseases andchronic hepatitis C.

As used herein, the terms “protein”, “polypeptide” and “peptide” areused interchangeably to refer to two or more amino acids linkedtogether. Except where indicated otherwise, e.g., for the abbreviationsfor the uncommon or unnatural amino acids set forth herein, thethree-letter and one-letter abbreviations, as used in the art, are usedherein to represent amino acid residues. Except when preceded with “D-”,the amino acid is an L-amino acid. Groups or strings of amino acidabbreviations are used to represent peptides. Except when specificallyindicated, peptides are indicated with the N-terminus on the left andthe sequence is written from the N-terminus to the C-terminus.

The term “peptide analogue” in the context of the present inventionrefers to a molecule in which a first peptide moiety is attached (i.e.coupled or linked), either directly or via a linking (i.e. bridging orspacing) chemical moiety, to a second peptide moiety, by means ofcovalent chemical bonding. In certain embodiments, a peptide analogue isa peptide described herein comprising an X peptide sequence and a Ypeptide sequence. In certain embodiments, a peptide analogue is apeptide described herein comprising an X′ peptide sequence and a Y′peptide sequence. In certain embodiments, a peptide analogue is apeptide described herein comprising an X″ peptide sequence and a Y″peptide sequence. In certain embodiments, a peptide analogue is apeptide described herein comprising an X peptide sequence and/or a Ypeptide sequence conjugated to an additional chemical moiety. In certainembodiments, a peptide analogue is a peptide described herein comprisingan X′ peptide sequence and/or a Y′ peptide sequence conjugated to anadditional chemical moiety. In certain embodiments, a peptide analogueis a peptide described herein comprising an X″ peptide sequence and/or aY″ peptide sequence conjugated to an additional chemical moiety. Thepeptides of the present invention described herein are peptideanalogues. Peptide analogues also include any of the peptide dimersdescribed herein.

Peptides and peptide dimers of the present invention may also bereferred to herein as compounds or peptide analogues.

The term “conservative substitution” as used herein denotes that one ormore amino acids are replaced by another, biologically similar residue.Examples include substitution of amino acid residues with similarcharacteristics, e.g., small amino acids, acidic amino acids, polaramino acids, basic amino acids, hydrophobic amino acids and aromaticamino acids. See, for example, the table below. In some embodiments ofthe invention, one or more Met residues are substituted with norleucine(Nle) which is a bioisostere for Met, but which, as opposed to Met, isnot readily oxidized. Another example of a conservative substitutionwith a residue normally not found in endogenous, mammalian peptides andproteins is the conservative substitution of Arg or Lys with, forexample, ornithine, canavanine, aminoethylcysteine or another basicamino acid. In some embodiments, one or more cysteines of a peptideanalogue of the invention may be substituted with another residue, suchas a serine. For further information concerning phenotypically silentsubstitutions in peptides and proteins, see, for example, Bowie et.al.Science 247, 1306-1310, 1990. In the scheme below, conservativesubstitutions of amino acids are grouped by physicochemical properties.I: neutral, hydrophilic, II: acids and amides, III: basic, IV:hydrophobic, V: aromatic, bulky amino acids.

I II III IV V A N H M F S D R L Y T E K I W P Q V G C

In the scheme below, conservative substitutions of amino acids aregrouped by physicochemical properties. VI: neutral or hydrophobic, VII:acidic, VIII: basic, IX: polar, X: aromatic.

VI VII VIII IX X A E H M F L D R S Y I K T W P C G N V Q

In certain embodiments, the present invention provides peptides whichare useful in the study and treatment of diseases of iron metabolism.

Throughout the present specification, unless naturally occurring aminoacids are referred to by their full name (e.g. alanine, arginine, etc.),they are designated by their conventional three-letter or single-letterabbreviations (e.g. Ala or A for alanine, Arg or R for arginine, etc.).In the case of less common or non-naturally occurring amino acids,unless they are referred to by their full name (e.g. sarcosine,ornithine, etc.), frequently employed three- or four-character codes areemployed for residues thereof, including, Sar or Sarc (sarcosine, i.e.N-methylglycine), Aib (α-aminoisobutyric acid), Dab (2,4-diaminobutanoicacid), Dapa (2,3-diaminopropanoic acid), γ-Glu (γ-glutamic acid), Gaba(γ-aminobutanoic acid), β-Pro (pyrrolidine-3-carboxylic acid), and 8Ado(8-amino-3,6-dioxaoctanoic acid), Abu (4-amino butyric acid), bhPro(β-homoproline), bhPhe homophenylalanine) and Dpa (β,β diphenylalanine),and Ida (Iminodiacetic acid).

As is clear to the skilled artisan, the peptide sequences disclosedherein are shown proceeding from left to right, with the left end of thesequence being the N-terminus of the peptide and the right end of thesequence being the C-terminus of the peptide. Among sequences disclosedherein are sequences incorporating a “Hy-” moiety at the amino terminus(N-terminus) of the sequence, and either an “—OH” moiety or an “—NH₂”moiety at the carboxy terminus (C-terminus) of the sequence. In suchcases, and unless otherwise indicated, a “Hy-” moiety at the N-terminusof the sequence in question indicates a hydrogen atom [e.g., R¹, R¹′, orR¹″=hydrogen (Hy-) in formula I, I′, or I″, respectively, correspondingto the presence of a free primary or secondary amino group at theN-terminus], while an “—OH” or an “—NH₂” moiety at the C-terminus of thesequence indicates a hydroxy group [e.g., R², R²′, or R²″═OH in formulaI, I′, or I″, respectively, corresponding to the presence of a carboxy(COOH) group at the C-terminus] or an amino group [e.g., R², R²′, orR²″═NH₂ in formula I, I′, or I″, respectively, corresponding to thepresence of an amido (CONH₂) group at the C-terminus], respectively. Ineach sequence of the invention, a C-terminal “—OH” moiety may besubstituted for a C-terminal “—NH₂” moiety, and vice-versa. Furthermore,R¹, R¹′, or R¹″ can in all sequences be substituted with isovalericacids or equivalent. In some embodiments, wherein a peptide of thepresent invention is conjugated to an acidic compound such as, e.g.,isovaleric acid, isobutyric acid, valeric acid, and the like, thepresence of such a conjugation is referenced in the acid form. So, forexample, but not to be limited in any way, instead of indicating aconjugation of isovaleric acid to a peptide DTHFPCIKFCK (SEQ ID NO:215)by referencing isovaleroyl (e.g., isovaleroyl-DTHFPCIKFCK [SEQ IDNO:215]), in some embodiments, the present application references such aconjugation as isovaleric acid—DTHFPCIKFCK (SEQ ID NO:215). Unlessotherwise indicated, reference is made to the L-isomeric forms of theamino acids in question. Where appropriate, the D-isomeric form of anamino acid is indicated in the conventional manner by the prefix “D”before the conventional three-letter code (e.g., DAsp or D-Asp; DPhe orD-Phe).

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of, the following structural formula:

R¹—X—Y—R² (I) (SEQ ID NO:12)

-   or a pharmaceutically acceptable salt or solvate thereof, wherein-   R¹ is hydrogen, an C1-C6 alkyl, C6-C12 aryl, C6-C12 aryl C1-C6    alkyl, C1-C20 alkanoyl (e.g., methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g., PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R² is —NH₂ or —OH;-   X is a peptide sequence having the formula (Ia)

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia) (SEQ ID NO:1)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Lys, Ala, or D-His;-   X4 is Phe, Ala, Dpa, bhPhe, or D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   Y is absent or Y is a peptide having the formula (IIa)

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15   (IIa) (SEQ ID NO:5)

-   wherein-   Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent;-   Y2 is Pro, Ala, Cys, Gly or absent;-   Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent;-   Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent;-   Y5 is Lys, Met, Arg, Ala or absent;-   Y6 is Gly, Ser, Lys, Ile, Arg, Ala, Pro, Val or absent;-   Y7 is Trp, Lys, Gly, Ala Ile, Val or absent;-   Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or    absent;-   Y9 is Cys, Tyr or absent;-   Y10 is Met, Lys, Arg, Tyr or absent;-   Y11 is Arg, Met, Cys, Lys or absent;-   Y12 is Arg, Lys, Ala or absent;-   Y13 is Arg, Cys, Lys, Val or absent;-   Y14 is Arg, Lys, Pro, Cys, Thr or absent; and-   Y15 is Thr, Arg or absent;-   wherein if Y is absent from the peptide of formula (I), X7 is Ile;    and-   wherein said compound of formula (I) is optionally PEGylated on R¹,    X, or Y.

In some embodiments, the compound or peptide of formula (I) comprisestwo or more cysteine residues, wherein at least two of said cysteineresidues are linked via a disulfide bond.

In some embodiments, X is a peptide sequence according to formula (Ia),described herein,

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Lys, Ala, or D-His;-   X4 is Phe, Ala, Dpa, or bhPhe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent.

In some embodiments, X is a peptide sequence according to formula (Ia),described herein, wherein

-   X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;-   X2 is Thr, Ala, or D-Thr;-   X3 is His, Lys, or D-His;-   X4 is Phe, Ala, or Dpa;-   X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;-   X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;-   X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;-   X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;-   X9 is Phe or bhPhe; and-   X10 is Lys, Phe or absent.

In some embodiments, X is a peptide sequence having the formula (Ib)

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib) (SEQ ID NO:2)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys, Phe or absent;

In some embodiments, X is a peptide sequence according to formula (Ib),as described herein, wherein

-   X1 is Asp, Glu, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments, X is a peptide sequence having the formula (Ic)

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic) (SEQ ID NO:3)

-   wherein-   X1 is Asp, Glu, Ida, pGlu, bhAsp or absent;-   X4 is: Phe or Dpa;-   X5 is Pro or bhPro;-   X8 is Ile Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments, X is a peptide sequence having the formula (Id)

X1-Thr-His-Phe-X5-Cys-Ile-X8-Phe-X10   (Id) (SEQ ID NO:4)

-   wherein-   X1 is Asp, Glu, or Ida;-   X4 is: Phe;-   X5 is Pro or bhPro;-   X8 is Ile, Lys or Phe; and-   X10 is absent.

In some embodiments, Y is a peptide sequence having the formula IIb

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10   (IIb) (SEQ ID NO:6)

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp, Ala or absent;-   Y8 is Val, Thr, Lys, Ala, Glu or absent; and-   Y10 is Met, Lys or absent.

In some embodiments, Y is a peptide sequence according to formula (IIb),as described herein,

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp or Ala;-   Y8 is Val, Thr, Ala, or Glu; and-   Y10 is Met, Lys or absent.

In some embodiments, Y is a peptide sequence having the formula (IIc)

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10   (IIc) (SEQ ID NO:7)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro or Gly;-   Y3 is Arg or Lys;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In some embodiments, Y is a peptide sequence having the formula (IId)

Y1-Cys-Y3-Y4-Arg-Y6-Y7-Y8-Cys-Y10-Y11-Y12-Y13-Y14-Y15   (IId) (SEQ IDNO:8)

-   wherein-   Y1 is Val, Ala or absent;-   Y3 is Gly, Pro or absent;-   Y4 is His, Trp or Tyr;-   Y6 is Ser, Gly or Pro;-   Y7 is Ile, Gly or Lys;-   Y8 is Gly, Met or absent;-   Y10 is Tyr or Cys;-   Y11 is Arg, Lys, Met or Ala;-   Y12 is Arg or Ala;-   Y13 is Cys or Val or absent;-   Y14 is Cys, Lys, Pro, Arg, Thr or absent; and-   Y15 is Arg, Thr or absent.

In some embodiments, Y is a peptide sequence having the formula (IIe)

Val-Cys-Y3-His-Arg-Y6-Y7-Y8-Cys-Tyr-Arg-Y12-Y13-Y14-Y15   (IIe) (SEQ IDNO:9)

-   wherein-   Y3 is Gly or absent;-   Y6 is Ser or Pro;-   Y7 is Ile or Lys;-   Y8 is Gly or absent;-   Y12 is Arg or Ala;-   Y13 is Cys, Val or absent;-   Y14 is Cys, Arg, Thr or absent; and-   Y15 is Arg or absent.

In some embodiments, Y is a peptide sequence having the formula (IIf)

Y1-Pro-Y3-Ser-Y5-Y6-Y7-Y8-Cys-Y10   (IIf) (SEQ ID NO:10)

-   wherein-   Y1 is Gly, Glu, Val, or Lys;-   Y3 is Arg or Lys;-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg;-   Y7 is Trp or absent;-   Y8 is Val, Thr, Asp, Glu or absent; and-   Y10 is Lys or absent.

In some embodiments, Y is a peptide sequence having the formula (IIg)

Y1-Pro-Y3-Ser-Y5-Y6-Y7-Y8-Cys-Y10   (IIg) (SEQ ID NO:11)

-   wherein-   Y1 is Glu or Lys;-   Y3 is Arg or Lys;-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg;-   Y7 is Trp or absent;-   Y8 is Val or absent; and-   Y10 is Lys or absent.

In some embodiments, the peptide of formula (I) comprises at leastthree, at least four, at least five, at least six, at least seven, atleast eight, at least nine, at least ten, at least eleven, at leasttwelve, at least thirteen, at least fourteen or at least fifteen Yresidues in Y.

In some embodiments, Y1 to Y3 are present and Y4 to Y15 are absent.

In some embodiments, Y1 to Y11 are present and Y12 to Y15 are absent.

In some embodiments, Y1 to Y10 are present and Y11 to Y15 are absent.

In some embodiments, Y8 and Y15 are absent.

In some embodiments, Y3 and Y15 are absent

In some embodiments, Y3, Y14 and Y15 are absent.

In some embodiment Y5 is absent.

In some embodiments Y1, Y5, Y7, Y12, Y13, Y14 and Y15 are absent.

In some embodiments Y1, Y5, and Y7 are absent. In some embodiments, Y8is absent. In some embodiments, Y3 is absent. In some embodiments Y1,Y5, Y7, and Y11-Y15 are absent. In some embodiments, Y8 and Y11-Y15 areabsent. In some embodiments, Y3 and Y11-Y15 are absent.

In some embodiments, the present invention provides a compound offormula (I), wherein the compound comprises any one of the X/Y peptidesequence formula combinations presented in Table 1 below.

TABLE 1 Illustrative combinations of X and Y peptides of a compound ofFormula (I) Formula I combinations X Peptide Y Peptide CombinationSequence Sequence Number Formula Formula 1 Ia IIa 2 Ia IIb 3 Ia IIc 4 IaIId 5 Ia IIe 6 Ia IIf 7 Ia IIg 8 Ib IIa 9 Ib IIb 10 Ib IIc 11 Ib IId 12Ib IIe 13 Ib IIf 14 Ib IIg 15 Ic IIa 16 Ic IIb 17 Ic IIc 18 Ic IId 19 IcIIe 20 Ic IIf 21 Ic IIg 22 Id IIa 23 Id IIb 24 Id IIc 25 Id IId 26 IdIIe 27 Id IIf 28 Id IIg

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of, the following structural formula:

R¹′—X′—Y′—R²′  (I′) (SEQ ID NO:21)

-   or a pharmaceutically acceptable salt or solvate thereof, wherein-   R¹′ is hydrogen, an C₁-C₆ alkyl, C₆-C₁₂ aryl, C₆-C₁₂ aryl C₁-C₆    alkyl, C₁-C₂₀ alkanoyl (e.g., methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g., PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R²′ is —NH₂ or —OH;-   X′ is a peptide sequence having the formula (Ia′)

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia′) (SEQ ID NO:13)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Lys, Ala, or D-His;-   X4 is Phe, Ala, Dpa, bhPhe or D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   and provided that if Y′ is absent, X7 is Ile; and-   Y′ is a peptide having the formula (IIa′)

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15   (IIa′) (SEQ IDNO:16)

-   wherein-   Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Ser or absent;-   Y2 is Pro, Ala, Cys, Gly or absent;-   Y3 is Arg, Lys, Pro, Gly, His, Ala, Trp or absent;-   Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr or absent;-   Y5 is Lys, Met, Arg, Ala or absent;-   Y6 is Gly, Ser, Lys, Ile, Arg, Ala, Pro, Val or absent;-   Y7 is Trp, Lys, Gly, Ala Ile, Val or absent;-   Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or    absent;-   Y9 is Cys, Tyr or absent;-   Y10 is Met, Lys, Arg, Tyr or absent;-   Y11 is Arg, Met, Cys, Lys or absent;-   Y12 is Arg, Lys, Ala or absent;-   Y13 is Arg, Cys, Lys, Val or absent;-   Y14 is Arg, Lys, Pro, Cys, Thr or absent; and-   Y15 is Thr, Arg or absent;-   wherein said compound of formula (I′) is optionally PEGylated on    R¹′, X′, or Y′; and-   wherein when said compound of formula (I′) comprises two or more    cysteine residues, at least two of said cysteine residues being    linked via a disulfide bond.

In some embodiments, R¹′ is hydrogen, isovaleric acid, isobutyric acidor acetyl.

In some embodiments of the peptide compound of formula (I′), X′ is apeptide sequence according to formula (Ia′), wherein

-   X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;-   X2 is Thr, Ala, or D-Thr;-   X3 is His, Lys, D-His or Lys;-   X4 is Phe, Ala, Dpa or D-Phe;-   X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;-   X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;-   X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;-   X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;-   X9 is Phe or bhPhe; and-   X10 is Lys, Phe or absent.

In some embodiments of the peptide compound of formula I′, X′ is apeptide sequence having the formula (Ib′)

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib′) (SEQ ID NO:14)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments of the peptide compound of formula I′, X′ is apeptide sequence having the formula (Ic′)

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic′) (SEQ ID NO:15)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is: Phe or Dpa;-   X5 is Pro or bhPro;-   X8 is Ile Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent;

In some embodiments of the peptide compound of formula I′, X′ is apeptide sequence having the formula (Id′)

X1-Thr-His-Phe-X5-Cys-Ile-X8-Phe-X10   (Id′) (SEQ ID NO:4)

-   wherein-   X1 is Asp, Glu, or Ida;-   X4 is: Phe;-   X5 is Pro or bhPro;-   X8 is Ile, Lys, or Phe; and-   X10 is absent;

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IIb′)

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10   (IIb′) (SEQ ID NO:17)

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp or Ala;-   Y8 is Val, Thr, Ala or Glu; and-   Y10 is Met, Lys or absent.

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IIc′)

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10   (IIc′) (SEQ ID NO:18)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro or Gly;-   Y3 is Arg or Lys;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IId′)

Y1-Cys-Y3-Y4-Arg-Y6-Y7-Y8-Cys-Y10-Y11-Y12-Y13-Y14-Y15   (IId′) (SEQ IDNO:19)

-   wherein-   Y1 is Val or Ala or absent;-   Y3 is Gly, Pro or absent;-   Y4 is His, Trp or Tyr;-   Y6 is Ser, Gly or Pro;-   Y7 is Ile, Gly or Lys;-   Y8 is Gly, Met or absent;-   Y10 is Tyr or Cys;-   Y11 is Arg, Lys, Met or Ala;-   Y12 is Arg or Ala;-   Y13 is Cys or Val or absent;-   Y14 is Cys, Lys, Pro, Arg, Thr or absent; and-   Y15 is Arg, Thr or absent.

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IIe′)

Val-Cys-Y3-His-Arg-Y6-Y7-Y8-Cys-Tyr-Arg-Y12-Y13-Y14-Y15   (IIe′) (SEQ IDNO:20)

-   wherein-   Y3 is Gly or absent;-   Y6 is Ser or Pro;-   Y7 is Ile or Lys;-   Y8 is Gly or absent;-   Y12 is Arg or Ala;-   Y13 is Cys, Val or absent;-   Y14 is Cys, Arg, Thr or absent; and-   Y15 is Arg or absent.

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IIf′)

Y1-Pro-Y3-Ser-Y5-Y6-Y7-Y8-Cys-Y10   (IIf) (SEQ ID NO:10)

-   wherein-   Y1 is Gly, Glu, Val, or Lys;-   Y3 is Arg or Lys;-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg;-   Y7 is Trp or absent;-   Y8 is Val, Thr, Asp, Glu or absent; and-   Y10 is Lys or absent.

In some embodiments of the peptide compound of formula I′, Y′ is apeptide sequence having the formula (IIg′)

Y1-Pro-Y3-Ser-Y5-Y6-Y7-Y8-Cys-Y10   (IIg′) (SEQ ID NO:11)

-   wherein-   Y1 is Glu or Lys;-   Y3 is Arg or Lys;-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg;-   Y7 is Trp or absent;-   Y8 is Val or absent; and-   Y10 is Lys or absent.

In some embodiments, the peptide of formula I′ comprises at least three,at least four, at least five, at least six, at least seven, at leasteight, at least nine, at least ten, at least eleven, at least twelve, atleast thirteen, at least fourteen or at least fifteen Y residues in Y′.

In some embodiments, Y1 to Y3 are present and Y4 to Y15 are absent.

In some embodiments, Y1 to Y11 are present and Y12 to Y15 are absent.

In some embodiments, Y1 to Y10 are present and Y11 to Y15 are absent.

In some embodiments, Y8 and Y15 are absent.

In some embodiments, Y3 and Y15 are absent

In some embodiments, Y3, Y14 and Y15 are absent.

In some embodiment Y5 is absent.

In some embodiments Y1, Y5, Y7, Y12, Y13, Y14 and Y15 are absent.

In some embodiments, the present invention provides a compound offormula (I′), wherein the compound comprises any one of the X′/Y′peptide sequence formula combinations presented in Table 2 below.

TABLE 2 Illustrative combinations of X′ and Y′ peptides of a compound ofFormula (I′) Formula I′ combinations X′ Peptide Y′ Peptide CombinationSequence Sequence Number Formula Formula 1 Ia′ IIa′ 2 Ia′ IIb′ 3 Ia′IIc′ 4 Ia′ IId′ 5 Ia′ IIe′ 6 Ia′ IIf′ 7 Ia′ IIg′ 8 Ib′ IIa′ 9 Ib′ IIb′10 Ib′ IIc′ 11 Ib′ IId′ 12 Ib′ IIe′ 13 Ib′ IIf′ 14 Ib′ IIg′ 15 Ic′ IIa′16 Ic′ IIb′ 17 Ic′ IIc′ 18 Ic′ IId′ 19 Ic′ IIe′ 20 Ic′ IIf′ 21 Ic′ IIg′22 Id′ IIa′ 23 Id′ IIb′ 24 Id′ IIc′ 25 Id′ IId′ 26 Id′ IIe′ 27 Id′ IIf′28 Id′ IIg′

In some embodiments, the invention provides peptides, which may beisolated and/or purified, comprising, consisting essentially of, orconsisting of, the following structural formula:

R¹″-X″-Y″-R²″  (I″) (SEQ ID NO:27)

-   or a pharmaceutically acceptable salt or solvate thereof, wherein-   R¹″ is hydrogen, an C₁-C₆ alkyl, C₆-C₁₂ aryl, C₆-C₁₂ aryl C₁-C₆    alkyl, C₁-C₂₀ alkanoyl (e.g., methyl, acetyl, formyl, benzoyl or    trifluoroacetyl, isovaleric acid, isobutyric acid, octanoic acid,    lauric acid and hexadecanoic acid), γ-Glu-hexadecanoic acid) or    pGlu, appended to the N-terminus, and including PEGylated versions    (e.g., PEG3 to PEG11), alone or as spacers of any of the foregoing;-   R²″ is —NH₂ or —OH;-   X″ is a peptide sequence having the formula (Ia″)

X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia″) (SEQ ID NO:22)

-   wherein-   X1 is Asp, Glu, Ala, Gly, Thr, Ida, pGlu, bhAsp, D-Asp, Tyr, Leu or    absent;-   X2 is Thr, Ala, Aib, D-Thr, Arg or absent;-   X3 is His, Lys, Ala, D-His or Lys;-   X4 is Phe, Ala, Dpa, bhPhe or D-Phe;-   X5 is Pro, Glu, Ser, Gly, Arg, Lys, Val, Ala, D-Pro, bhPro, Sarc,    Abu or absent;-   X6 is Ile, Cys, Arg, Leu, Lys, His, Glu, D-Ile, D-Arg, D-Cys, Val,    Ser or Ala;-   X7 is Cys, Ile, Ala, Leu, Val, Ser, Phe, Dapa, D-Ile or D-Cys;-   X8 is Ile, Lys, Arg, Ala, Gln, Phe, Glu, Asp, Tyr, Ser, Leu, Val,    D-Ile, D-Lys, D-Arg, or Dapa;-   X9 is Phe, Ala, Ile, Tyr, Lys, Arg, bhPhe or D-Phe; and-   X10 is Lys, Phe or absent;-   and provided that if Y″ is absent, X7 is Ile;-   wherein said compound of formula I″ is optionally PEGylated on R¹″,    X″, or Y″; and-   wherein when said compound of formula I″ comprises two or more    cysteine residues, at least two of said cysteine residues being    linked via a disulfide bond.

In some embodiments, Y″ is absent.

In some embodiments, R¹″ is hydrogen, isovaleric acid, isobutyric acidor acetyl.

In some embodiments of the compound of formula (I″), X″ is a peptidesequence according to formula (Ia″), wherein

-   X1 is Asp, Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent;-   X2 is Thr, Ala, or D-Thr;-   X3 is His, Lys, or D-His;-   X4 is Phe, Ala, or Dpa;-   X5 is Pro, Gly, Arg, Lys, Ala, D-Pro or bhPro;-   X6 is Ile, Cys, Arg, Lys, D-Ile or D-Cys;-   X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys;-   X8 is Ile, Arg, Phe, Gln, Lys, Glu, Val, Leu or D-Ile;-   X9 is Phe or bhPhe; and-   X10 is Lys or absent.

In some embodiments of the compound of formula (I″), X″ is a peptidesequence having the formula (Ib″)

X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib″) (SEQ ID NO:23)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X6 is Ile, Cys or Arg;-   X7 is Cys, Ile, Leu or Val;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys, Phe or absent.

In some embodiments of the compound of formula (I″), X″ is a peptidesequence having the formula (Ic″)

X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic″) (SEQ ID NO:24)

-   wherein-   X1 is Asp, Ida, pGlu, bhAsp or absent;-   X4 is Phe or Dpa;-   X5 is Pro or bhPro;-   X8 is Ile, Lys, Glu, Phe, Gln or Arg; and-   X10 is Lys or absent.

In some embodiments of the compound of formula (I″), X″ is a peptidesequence having the formula (Id″)

X1-Thr-His-Phe-X5-Cys-Ile-X8-Phe-X10   (Id″) (SEQ ID NO:4)

-   wherein-   X1 is Asp, Glu or Ida;-   X4 is Phe;-   X5 is Pro or bhPro;-   X8 is Ile, Lys, or Phe; and-   X10 is absent.

In some embodiments of the compound of formula (I″), Y″ is a peptidehaving the formula (IIa″)

Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Cys-Y10   (IIa″) (SEQ ID NO:25)

-   wherein-   Y1 is Gly, Ala, Lys, Pro or D-Pro;-   Y2 is Pro, Ala or Gly;-   Y3 is Arg, Ala, Lys or Trp;-   Y4 is Ser, Gly or Ala;-   Y5 is Lys, Met, Arg or Ala;-   Y6 is Gly, Arg or Ala;-   Y7 is Trp Ala or absent;-   Y8 is Val, Thr, Lys, Ala, Glu or absent; and-   Y10 is Met, Lys or absent.

In some embodiments of the compound of formula (I″), Y″ is a peptidesequence according to formula (IIa″) (SEQ ID NO:25)

-   wherein-   Y1 is Gly, Glu, Val, or Lys-   Y2 is Pro-   Y3 is Arg or Lys;-   Y4 is Ser-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg-   Y7 is Trp or absent-   Y8 is Val, Thr, Asp, Glu or absent;-   Y10 is Lys or absent

In some embodiments of the compound of formula (I″), Y″ is a peptidesequence according to formula (IIa″) (SEQ ID NO:25)

-   wherein-   Y1 is Glu or Lys-   Y2 is Pro-   Y3 is Arg or Lys;-   Y4 is Ser-   Y5 is Arg or Lys;-   Y6 is Gly, Ser, Lys, Ile or Arg;-   Y7 is Trp or absent;-   Y8 is Val or absent;-   Y10 is Lys or absent

In some embodiments of the compound of formula (I″), Y″ is a peptidesequence according to formula (IIa″) (SEQ ID NO:25)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro or Gly;-   Y3 is Arg or Lys;-   Y4 is Ser;-   Y5 is Lys;-   Y6 is Gly;-   Y7 is Trp;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In some embodiments of the compound of formula (I″), Y″ is a peptidesequence having the formula (IIb″)

Y1-Y2-Y3-Ser-Lys-Gly-Trp-Y8-Cys-Y10   (IIb″) (SEQ ID NO:26)

-   wherein-   Y1 is Gly, Pro or D-Pro;-   Y2 is Pro or Gly;-   Y3 is Arg or Lys;-   Y8 is Val or Thr; and-   Y10 is Met, Lys or absent.

In some embodiments, the present invention provides a compound offormula (I″), wherein the compound comprises any one of the X″/Y″peptide sequence formula combinations presented in Table 3 below.

TABLE 3 Illustrative combinations of X″ and Y″ peptides of a compound ofFormula (I″) Formula I″ combinations X″ Peptide Y″ Peptide CombinationSequence Sequence Number Formula Formula 1 Ia″ IIa″ 2 Ia″ IIb″ 3 Ib″IIa″ 4 Ib″ IIb″ 5 Ic″ IIa″ 6 Ic″ IIb″ 7 Id″ IIa″ 8 Id″ IIb″

In some embodiments the peptide of formula (I″) comprises at leastthree, at least four, at least five, at least six, at least seven, atleast eight, at least nine, or at least ten Y residues in Y″. In someembodiments, Y1 to Y3 are present and Y4 to Y10 are absent. In someembodiments Y5 is absent. In some embodiments Y1, Y5, and Y7 are absent.In some embodiments, Y8 is absent. In some embodiments, Y3 is absent.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Leu. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Val. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Cys. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Ile. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Ile. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X8 is Ile. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein. In someembodiments, the present invention provides a compound of formula (I),(I′), or (I″), as described herein, each respectively comprising an X,X′, or X″ peptide sequence, according to the present disclosure, whereinX8 is Lys. In particular embodiments, formula (I) comprises (a) Ia, Ib,Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIc′, IId′, IIe′, IIf′,or IIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys and X7 is Ile. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIc′, IId′, IIe′, IIf′, or IIg′, as describedherein. In particular embodiments, formula (I″) comprises (i) Ia″, Ib″,Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys and X8 is Ile. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, and X8 is Ile. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Ile and X7 is Cys. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Cys and X8 is Ile. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Ile, X7 is Cys, and X8 is Ile. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys and X8 is Lys. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, and X8 is Lys. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys and C7 is Leu. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys and C7 is Val. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Ile and X8 is Lys. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Leu and X8 is Lys. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X7 is Val and X8 is Lys. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Leu and X8 is Lys. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Val, and X8 is Lys. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, Leu, or Val. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, Leu, or Val, and X8 is Lys. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is ASP or IDA, X6 is Cys, X7 is Ile, Leu, or Val,and X8 is Lys. In particular embodiments, formula (I) comprises (a) Ia,Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg,as described herein. In particular embodiments, formula (I′) comprises(a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′,IIe′, IIf′, or IIg′, as described herein. In particular embodiments,formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii)IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp or IDA, X6 is Cys, X7 is Ile, Leu, or Val,and X8 is Lys. In particular embodiments, formula (I) comprises (a) Ia,Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg,as described herein. In particular embodiments, formula (I′) comprises(a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′,IIe′, IIf′, or IIg′, as described herein. In particular embodiments,formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii)IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X2 is Thr, X6 is Cys, X7 is Ile, Leu, or Val, and X8is Lys. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X3 is His, X6 is Cys, X7 is Ile, Leu, or Val, and X8is Lys. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X4 is Phe, X6 is Cys, X7 is Ile, Leu, or Val, and X8is Lys. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X5 is Pro, X6 is Cys, X7 is Ile, Leu, or Val, and X8is Lys. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, Leu, or Val, X8 is Lys, and X9is Phe. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X2 is Thr, X6 is Cys, X7 is Ile and X8 is Lys. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X3 is His, X6 is Cys, X7 is Ile, and X8 is Lys. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X4 is Phe, X6 is Cys, X7 Ile, and X8 is Lys. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X5 is Pro, X6 is Cys, X7 Ile, and X8 is Lys. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X6 is Cys, X7 is Ile, X8 is Lys, and X9 is Phe. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X5 is Pro, X6 is Cys, X7 is Ile, X8 is Lys, and X9is Phe. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X4 is Phe, X5 is Pro, X6 is Cys, X7 is Ile, X8 isLys, and X9 is Phe. In particular embodiments, formula (I) comprises (a)Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, orIIg, as described herein. In particular embodiments, formula (I′)comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′,IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. In particularembodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and,optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X3 is His, X4 is Phe, X5 is Pro, X6 is Cys, X7 isIle, X8 is Lys, and X9 is Phe. In particular embodiments, formula (I)comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa, IIb, IIc, IId,IIe, IIf, or IIg, as described herein. In particular embodiments,formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and, optionally, (b)IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, as described herein. Inparticular embodiments, formula (I″) comprises (i) Ia″, Ib″, Ic″, or Id″and, optionally, (ii) IIa″ or IIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X2 is Thr, X3 is His, X4 is Phe, X5 is Pro, X6 isCys, X7 is Ile, X8 is Lys, and X9 is Phe. In particular embodiments,formula (I) comprises (a) Ia, Ib, Ic, or Id and, optionally, (b) IIa,IIb, IIc, IId, IIe, IIf, or IIg, as described herein. In particularembodiments, formula (I′) comprises (a) Ia′, Ib′, Ic′, or Id′ and,optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, or IIg′, asdescribed herein. In particular embodiments, formula (I″) comprises (i)Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, as describedherein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp or IDA, X2 is Thr, X3 is His, X4 is Phe,X5 is Pro, X6 is Cys, X7 is Ile, X8 is Lys, and X9 is Phe. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp or IDA, X2 is Thr, X3 is His, X4 is Phe,X5 is Pro, X6 is Cys, X7 is Ile, Leu, or Val, X8 is Lys, and X9 is Phe.In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Idand, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp, X2 is Thr, X3 is His, X4 is Phe, X5 isPro X6 is Cys, X7 is Ile, X8 is Lys, and X9 is Phe. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or asdescribed herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is IDA, X2 is Thr, X3 is His, X4 is Phe, X5 isPro, X6 is Cys, X7 is Ile, X8 is Lys, and X9 is Phe. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIc′, IId′, IIe′, IIf′, or IIg′,as described herein. In particular embodiments, formula (I″) comprises(i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, asdescribed herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, wherein the compoundcomprises an R¹ that is isovaleric acid.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp or IDA, X2 is Thr, X3 is His, X4 is Phe,X5 is Pro, X6 is Cys, X7 is Ile, Leu, or Val, X8 is Lys, and X9 is Phe;wherein said peptide further comprises an R¹ that is isovaleric acid. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIc′, IId′, IIe′, IIf′, or IIg′,as described herein. In particular embodiments, formula (I″) comprises(i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′, asdescribed herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp, X2 is Thr, X3 is His, X4 is Phe, X5 isPro, X6 is Cys, X7 is Ile, Leu, or Val, and X8 is Lys; wherein saidpeptide further comprises an R¹ that is isovaleric acid. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp, X2 is Thr, X3 is His, X4 is Phe, X5 isPro, X6 is Cys, X7 is Ile, Leu, or Val, X8 is Lys, and X9 is Phe;wherein said peptide further comprises an R group that is isovalericacid. In particular embodiments, formula (I) comprises (a) Ia, Ib, Ic,or Id and, optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, asdescribed herein. In particular embodiments, formula (I′) comprises (a)Ia′, Ib′, Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′,IIf′, or IIg′, as described herein. In particular embodiments, formula(I″) comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ orIIb′, as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, each respectivelycomprising an X, X′, or X″ peptide sequence, according to the presentdisclosure, wherein X1 is Asp, X2 is Thr, X3 is His, X4 is Phe, X5 isPro, X6 is Cys, X7 is Ile, X8 is Lys, and X9 is Phe; wherein saidpeptide further comprises an R group that is isovaleric acid. Inparticular embodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In some embodiments, the present invention provides a compound offormula (I), (I′), or (I″), as described herein, wherein the compoundcomprises a peptide sequence that is 85% or higher (e.g., 85%, 90%, 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5%) homologous to an aminoacid sequence set forth in any one of Tables 5-15. In particularembodiments, formula (I) comprises (a) Ia, Ib, Ic, or Id and,optionally, (b) IIa, IIb, IIc, IId, IIe, IIf, or IIg, as describedherein. In particular embodiments, formula (I′) comprises (a) Ia′, Ib′,Ic′, or Id′ and, optionally, (b) IIa′, IIb′, IIc′, IId′, IIe′, IIf′, orIIg′, as described herein. In particular embodiments, formula (I″)comprises (i) Ia″, Ib″, Ic″, or Id″ and, optionally, (ii) IIa″ or IIb′,as described herein.

In certain embodiments, a peptide or a peptide dimer of the presentinvention comprises any one of the compounds shown in any one of Tables5-15.

In certain embodiments, a peptide or a peptide dimer of the presentinvention comprises any one of the amino acid sequences provided as SEQID NOS: 1-334 and 338-375, or as shown in any one of Tables 5-15

In certain embodiments, a peptide or a peptide dimer of the presentinvention comprises an amino acid sequence set forth in any one ofTables 5-15.

In certain embodiments, a peptide or a peptide dimer of the presentinvention has a structure shown in any one of Tables 5-15, e.g., Tables7 or 12-15. In one certain embodiment, a peptide or a peptide dimer ofthe present invention comprises an amino acid sequence set forth in anyone of Tables 5-15, e.g., Tables 7 or 12-15. In some embodiments, apeptide of the present invention comprises an amino acid sequence havingat least about 85% identical or at least about 90%, 95%, 97%, 98%, 99%identical to any amino acid sequence set forth in any one of Tables5-15, e.g., Tables 7 or 12-15, or any one of SEQ ID NOS: 1-334 and338-375. In one certain embodiment, a peptide or a peptide dimer of thepresent invention comprises an amino acid sequence having at least about85% identical or at least about 90%, 95%, 97%, 98%, 99% identical to anyamino acid sequence set forth in Table 7 or any one of Tables 5-15.

It is understood that in the context of the invention, a peptide orpeptide dimer comprising a peptide sequence shown in one of theaccompanying Tables or sequence listing may have certain minoralterations to one or more amino acid residues of the peptide sequence,as compared to the native amino acid, yet still be considered tocomprises the peptide sequence shown in the Tables or sequence listing.For example, one or more side chains of one or more amino acid residuespresent in the peptide or peptide dimer may be slightly altered due tothe attachment of a linker or dimerization via cysteine residues, or anN-terminal or C-terminal amino acid may be amidated.

In some embodiments, a peptide or a peptide dimer of the presentinvention exhibits hepcidin activity. In some embodiments, a peptide ora peptide dimer of the present invention exhibits at least about 50%,60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, greater than 99%, greater than100%, greater than 110%, greater than 120%, greater than 150%, greaterthan 200% greater than 500%, or greater than 1000% of the activity of areference hepcidin, (e.g., any one of the hepcidin reference compoundsprovided in Table 4). In some embodiments, the activity is an in vitroor an in vivo activity as described herein.

In some embodiments, a peptide or a peptide dimer of the presentinvention exhibits at least about 50%, 60%, 70%, 80%, 90%, 95%, 97%,98%, 99%, or greater than 99% of the in vitro activity for inducing thedegradation of human ferroportin protein as that of a referencehepcidin, (e.g., any one of the hepcidin reference compounds provided inTable 4), wherein the activity is measured according to the methodsdescribed herein (e.g., according to Example 2).

In some embodiments, a peptide or a peptide dimer of the presentinvention exhibits at least about 50%, 60%, 70%, 80%, 90%, 95%, 97%,98%, 99%, or greater than 99% of the in vivo activity for inducing thereduction of free plasma iron in an individual as does a referencehepcidin, (e.g., any one of the hepcidin reference compounds provided inTable 4), wherein the activity is measured according to the methodsdescribed herein (e.g., according to Example 8).

In some embodiments, a peptide or a peptide dimer of the presentinvention exhibits increased hepcidin activity as compared to a hepcidinreference peptide, (e.g., any one of the hepcidin reference compoundsprovided in Table 4). In certain embodiments, a peptide ora peptidedimer of the present invention exhibits 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100,120, 140, 160, 180, or 200-fold greater or at least about 10%, 20%, 30%,40%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500% , 700%, or1000% greater activity than a reference hepcidin, (e.g., any one of thehepcidin reference compounds provided in Table 4). In some embodiments,a peptide or a peptide dimer of the present invention exhibits at leastabout 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, or greater than 99%of the activity exhibited by a hepcidin reference compound. In someembodiments, the activity is an in vitro or an in vivo activity, e.g.,an in vivo or an in vitro activity described herein. In certainembodiments, a peptide or a peptide dimer of the present inventionexhibits 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, or200-fold greater or at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%,80%, 90%, 100%, 200%, 300%, 400%, 500% , 700%, or 1000% greater activitythan a reference hepcidin, (e.g., any one of the hepcidin referencecompounds provided in Table 4), wherein the activity is an in vitroactivity for inducing the degradation of ferropontin, e.g., as measuredaccording to Example 2; or wherein the activity is an in vivo activityfor reducing free plasma iron, e.g., as measured according to Example 8.

In some embodiments, a peptide or a peptide dimer of the presentinvention binds ferroportin, e.g., human ferroportin. In someembodiments, a peptide or a peptide dimer of the present inventionexhibits at least about 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, 99%, orgreater than 99% of the ferroportin binding ability that is exhibited bya reference hepcidin (e.g., any one of the hepcidin reference compoundsprovided in Table 4). In some embodiments, a peptide or a peptide dimerof the present invention has a lower IC₅₀ (i.e., higher bindingaffinity) for binding to ferroportin, (e.g., human ferroportin) comparedto a reference hepcidin, (e.g., any one of the hepcidin referencecompounds provided in Table 4). In some embodiments, the peptide of thepresent invention has an IC₅₀ in a ferroportin competitive binding assaywhich is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%,100%, 200%, 300%, 400%, 500% , 700%, or 1000% lower than a referencehepcidin, (e.g., any one of the hepcidin reference compounds provided inTable 4).

In some embodiments, the present invention provides a compound offormula I, I′, or I″, as described herein, wherein the peptide exhibitsincreased stability (e.g., as measured by half-life, rate of proteindegradation) as compared to a reference hepcidin, (e.g., any one of thehepcidin reference compounds provided in Table 4). In some embodiments,the present invention provides a dimer of such a compound, and incertain embodiments the dimer is a homodimer. In certain embodiments,the stability of a peptide or a peptide dimer of the present invenitonis increased at least about 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13,14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 140,160, 180, or 200-fold greater or at least about 10%, 20%, 30%, 40%, 50%,60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, or 500% greater than areference hepcidin, (e.g., any one of the hepcidin reference compoundsprovided in Table 4). In some embodiments, the stability is a stabilitythat is described herein. In some embodiments, the stability is a plasmastability, e.g., as optionally measured according to the methoddescribed in Example 7.

In particular embodiments, the present invention provides a compound offormula I, I′, or I″, as described herein, wherein the peptide exhibitsa longer half-life than a reference hepcidin, (e.g., any one of thehepcidin reference compounds provided in Table 4). In some embodiments,the present invention provides a dimer of such a compound, and incertain embodiments the dimer is a homodimer. In particular embodiments,a peptide or a peptide dimer of the present invention has a half-lifeunder a given set of conditions (e.g., temperature, pH) of at leastabout 5 minutes, at least about 10 minutes, at least about 20 minutes,at least about 30 minutes, at least about 45 minutes, at least about 1hour, at least about 2 hour, at least about 3 hours, at least about 4hours, at least about 5 hours, at least about 6 hours, at least about 12hours, at least about 18 hours, at least about 1 day, at least about 2days, at least about 4 days, at least about 7 days, at least about 10days, at least about two weeks, at least about three weeks, at leastabout 1 month, at least about 2 months, at least about 3 months, ormore, or any intervening half-life or range in between, about 5 minutes,about 10 minutes, about 20 minutes, about 30 minutes, about 45 minutes,about 1 hour, about 2 hour, about 3 hours, about 4 hours, about 5 hours,about 6 hours, about 12 hours, about 18 hours, about 1 day, about 2days, about 4 days, about 7 days, about 10 days, about two weeks, aboutthree weeks, about 1 month, about 2 months, about 3 months, or more, orany intervening half-life or range in between. In some embodiments, thehalf life of a peptide or a peptide dimer of the present invention isextended due to its conjugation to one or more lipophilic substituent,e.g., any of the lipophilic substituents disclosed herein. In someembodiments, the half life of a peptide or a peptide dimer of thepresent invention is extended due to its conjugation to one or morepolymeric moieties, e.g., any of the polymeric moieties disclosedherein. In certain embodiments, the temperature is about 25° C., about4° C., or about 37° C., and the pH is a physiological pH, or a pH about7.4.

In some embodiments, the half-life is measured in vitro using anysuitable method known in the art, e.g., in some embodiments, thestability of a peptide or a peptide dimer of the present invention isdetermined by incubating the peptide or the peptide dimer withpre-warmed human serum (Sigma) at 37° C. Samples are taken at varioustime points, typically up to 24 hours, and the stability of the sampleis analyzed by separating the peptide or peptide dimer from the serumproteins and then analyzing for the presence of the peptide or peptidedimer of interest using LC-MS.

In some embodiments, the stability of the peptide is measured in vivousing any suitable method known in the art, e.g., in some embodiments,the stability of a peptide or a peptide dimer is determined in vivo byadministering the peptide or peptide dimer to a subject such as a humanor any mammal (e.g., mouse) and then samples are taken from the subjectvia blood draw at various time points, typically up to 24 hours. Samplesare then analyzed as described above in regard to the in vitro method ofmeasuring half-life. In some embodiments, in vivo stability of a peptideor a peptide dimer of the present invention is determined via the methoddisclosed in Example 7.

In some embodiments, the present invention provides a compound offormula I, I′, or I″, as described herein, or a dimer thereof, whereinthe peptide or the dimer exhibits improved solubility or improvedaggregation characteristics as compared to a reference hepcidin, (e.g.,any one of the hepcidin reference compounds provided in Table 4).Solubility may be determined via any suitable method known in the art.In some embodiments, suitable methods known in the art for determiningsolubility include incubating peptides in various buffers (AcetatepH4.0, Acetate pH5.0, Phos/Citrate pH5.0, Phos Citrate pH6.0, Phos pH6.0, Phos pH 7.0, Phos pH7.5, Strong PBS pH 7.5, Tris pH7.5, Tris pH8.0, Glycine pH 9.0, Water, Acetic acid (pH 5.0 and other known in theart) and testing for aggregation or solubility using standardtechniques. These include, but are not limited to, visual precipitation,dynamic light scattering, Circular Dichroism and fluorescent dyes tomeasure surface hydrophobicity, and detect aggregation or fibrillation,for example. In some embodiments, improved solubility means the peptideis more soluble in a given liquid than is a reference hepcidin (e.g.,any one of the hepcidin reference compounds provided in Table 4).

In some embodiments, the present invention provides a compound offormula I, I′, or I″, as described herein, or a dimer thereof, whereinthe peptide or the dimer exhibits less degradation (i.e., moredegradation stability), e.g., greater than or about 10% less, greaterthan or about 20% less, greater than or about 30% less, greater than orabout 40 less, or greater than or about 50% less than a referencehepcidin (e.g., any one of the hepcidin reference compounds provided inTable 4). In some embodiments, degradation stability is determined viaany suitable method known in the art. In some embodiments, suitablemethods known in the art for determining degradation stability includethe method described in Hawe et al J Pharm Sci, VOL. 101, NO. 3, 2012, p895-913, incorporated herein in its entirety. Such methods are in someembodiments used to select potent sequences with enhanced shelf lifes.

In some embodiments, the present invention provides compositions andmedicaments comprising at least one peptide or peptide dimer asdisclosed herein. In some embodiments, the present invention provides amethod of manufacturing medicaments comprising at least one peptide orpeptide dimer as disclosed herein for the treatment of diseases of ironmetabolism, such as iron overload diseases. In some embodiments, thepresent invention provides a method of manufacturing medicamentscomprising at least one peptide or pepitde dimer as disclosed herein forthe treatment of diabetes (Type I or Type II), insulin resistance, orglucose intolerance. Also provided are methods of treating a disease ofiron metabolism in a subject, such as a mammalian subject, andpreferably a human subject, comprising administering at least onepeptide, peptide dimer, or composition as disclosed herein to thesubject. In some embodiments, the peptide, peptide dimer, or thecomposition is administered in a therapeutically effective amount. Alsoprovided are methods of treating diabetes (Type I or Type II), insulinresistance, or glucose intolerance in a subject, such as a mammaliansubject, and preferably a human subject, comprising administering atleast one peptide, peptide dimer, or composition as disclosed herein tothe subject. In some embodiments, the peptide, peptide dimer, orcomposition is administered in a therapeutically effective amount.

In some embodiments, thepeptide, or peptide dimer of this invention issynthetically manufactured. In other embodiments, the peptide or peptidedimer of this invention is recombinantly manufactured.

In some embodiments, the invention provides a process for manufacturinga compound, peptide, peptide analogue, peptide dimer, or pharmaceuticalcomposition as disclosed herein.

In some embodiments, the invention provides a device comprising at leastone peptide, peptide analogue, or peptide dimer of the presentinvention, or pharmaceutically acceptable salt or solvate thereof fordelivery of the peptide analogue or the peptide dimer to a subject.

In some embodiments, the present invention provides methods of binding aferroportin or inducing ferroportin internalization and degradationwhich comprises contacting the ferroportin with at least one peptide orpeptide analogue, peptide dimer, or composition as disclosed herein.

In some embodiments, the present invention provides kits comprising atleast one peptide, peptide analogue, peptide dimer, or composition asdisclosed herein packaged together with a reagent, a device,instructional material, or a combination thereof.

In some embodiments, the present invention provides complexes whichcomprise at least one peptide or peptide dimer as disclosed herein boundto a ferroportin, preferably a human ferroportin, or an antibody, suchas an antibody which specifically binds a peptide or a peptide dimer asdisclosed herein, Hep25, or a combination thereof.

In some embodiments, the compound has a measurement (e.g., an EC50) ofless than 500 nM within the Fpn internalization assay. As a skilledperson will realize, the function of the peptide is dependent on thetertiary structure of the peptide and the binding surface presented. Itis then possible to make minor changes of the sequence that do notaffect the fold or are not on the binding surface and maintain function.In other embodiments, the compound of the invention is a peptide orpeptidomimetic compound, or a dimer thereof having 85% or higher (e.g.,85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 99.5%)identity or homology to an amino acid sequence of any compound offormula I, I′, or I″ that exhibits an activity, or lessens a symptom ofa disease or indication for which hepcidin is involved.

In some embodiments, the peptide, peptide analogue, or dimer thereof ofthe invention may comprise functional fragments or variants thereof thathave at most 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid substitutionscompared to one or more of the specific sequences recited below.

In addition to the methods disclosed herein in Example 1, the peptidesand the peptide dimers of the present invention may be produced usingmethods known in the art including chemical synthesis, biosynthesis orin vitro synthesis using recombinant DNA methods, and solid phasesynthesis. See e.g. Kelly & Winkler (1990) Genetic EngineeringPrinciples and Methods, vol. 12, J. K. Setlow ed., Plenum Press, NY, pp.1-19; Merrifield (1964) J Amer Chem Soc 85:2149; Houghten (1985) PNASUSA 82:5131-5135; and Stewart & Young (1984) Solid Phase PeptideSynthesis, 2ed. Pierce, Rockford, Ill., which are herein incorporated byreference. The peptides of the present invention may be purified usingprotein purification techniques known in the art such as reverse phasehigh-performance liquid chromatography (HPLC), ion-exchange orimmunoaffinity chromatography, filtration or size exclusion, orelectrophoresis. See Olsnes, S. and A. Pihl (1973) Biochem.12(16):3121-3126; and Scopes (1982) Protein Purification,Springer-Verlag, NY, which are herein incorporated by reference.Alternatively, the peptides of the present invention may be made byrecombinant DNA techniques known in the art. Thus, polynucleotides thatencode the polypeptides of the present invention are contemplatedherein. In preferred embodiments, the polynucleotides are isolated. Asused herein “isolated polynucleotides” refers to polynucleotides thatare in an environment different from that in which the polynucleotidenaturally occurs.

In certain embodiments, peptides of the present invention bindferroportin, preferably human ferroportin. Preferred peptides of thepresent invention specifically bind human ferroportin. As used herein,“specifically binds” refers to a specific binding agent's preferentialinteraction with a given ligand over other agents in a sample. Forexample, a specific binding agent that specifically binds a givenligand, binds the given ligand, under suitable conditions, in an amountor a degree that is observable over that of any nonspecific interactionwith other components in the sample. Suitable conditions are those thatallow interaction between a given specific binding agent and a givenligand. These conditions include pH, temperature, concentration,solvent, time of incubation, and the like, and may differ among givenspecific binding agent and ligand pairs, but may be readily determinedby those skilled in the art.

The peptides of the present invention that mimic the hepcidin activityof Hep25, the bioactive human 25-amino acid form, are herein referred toas “mini-hepcidins”. As used herein, in certain embodiments, a compoundhaving “hepcidin activity” means that the compound has the ability tolower plasma iron concentrations in subjects (e.g. mice or humans), whenadministered thereto (e.g. parenterally injected or orallyadministered), in a dose-dependent and time-dependent manner. See e.g.as demonstrated in Rivera et al. (2005), Blood 106:2196-9. In someembodiments, the peptides of the present invention lower the plasma ironconcentration in a subject by at least about 1.2, 1.5, 2, 3, 4, 5, 6, 7,8, 9, or 10-fold, or at least about 5%, 10%, 20%, 25%, 30%, 40%, 50%,60%, 70%, 80%, 90%, or about 99%.

In some embodiments, the peptides of the present invention have in vitroactivity as assayed by the ability to cause the internalization anddegradation of ferroportin in a ferroportin-expressing cell line astaught in Nemeth et al. (2006) Blood 107:328-33. In vitro activity maybe measured by the dose-dependent loss of fluorescence of cellsengineered to display ferroportin fused to green fluorescent protein asin Nemeth et al. (2006) Blood 107:328-33. Aliquots of cells areincubated for 24 hours with graded concentrations of a referencepreparation of Hep25 or a mini-hepcidin. As provided herein, the EC50values are provided as the concentration of a given compound (e.g.peptide) that elicits 50% of the maximal loss of fluorescence generatedby the reference Hep25 preparation. EC50 of Hep25 preparations in thisassay range from 5 to 15 nM and preferred mini-hepcidins have EC50values in in vitro activity assays of about 1,000 nM or less. In certainembodiments, a peptide of the present invention has an EC50 in an invitro activity assay (e.g., as described in Nemeth et al. (2006) Blood107:328-33 or Example 2 herein) of less than about any one of 0.01,0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60,70, 80, 90, 100, 200 or 500 nM. In some embodiments, a peptide analogueor biotherapeutic composition has an EC₅₀ value of about 1 nM or less.

Other methods known in the art for calculating the hepcidin activity andin vitro activity of peptides according to the present invention may beused. For example, the in vitro activity of compounds may be measured bytheir ability to internalize cellular ferroportin, which is determinedby immunohistochemistry or flow cytometry using antibodies whichrecognizes extracellular epitopes of ferroportin. Alternatively, the invitro activity of compounds may be measured by their dose-dependentability to inhibit the efflux of iron from ferroportin-expressing cellsthat are preloaded with radioisotopes or stable isotopes of iron, as inNemeth et al. (2006) Blood 107:328-33.

Conjugation

The skilled person will be well aware of suitable techniques forpreparing the compounds employed in the context of the invention. Forexamples of suitable chemistry, see, e.g., WO98/08871, WO00/55184,WO00/55119, Madsen et al (J. Med. Chem. 2007, 50, 6126-32), and Knudsenet al. 2000 (J. Med Chem. 43, 1664-1669).

The side chains of one or more amino acid residues (e.g. Lys residues)in a compound of the invention may be further conjugated (i.e.covalently attached) to a lipophilic substituent. The lipophilicsubstituent may be covalently bonded to an atom in the amino acid sidechain, or alternatively may be conjugated to the amino acid side chainvia one or more spacers. The amino acid(s) in question may be part ofthe peptide moiety X, or a part of the peptide moiety Y.

Without wishing to be bound by any particular theory, it is believedthat the lipophilic substituent binds to albumin in the blood stream,thereby shielding the peptide analogue of the invention from enzymaticdegradation, and thus enhancing its half-life. The spacer, when present,may provide spacing between the peptide analogue and the lipophilicsubstituent.

In certain embodiments, the lipophilic substituent may comprise ahydrocarbon chain having from 4 to 30 C atoms, for example at least 8 or12 C atoms, and preferably 24 C atoms or fewer, or 20 C atoms or fewer.The hydrocarbon chain may be linear or branched and may be saturated orunsaturated. In certain embodiments, the hydrocarbon chain issubstituted with a moiety which forms part of the attachment to theamino acid side chain or the spacer, for example an acyl group, asulfonyl group, an N atom, an O atom or an S atom. In some embodiments,the hydrocarbon chain is substituted with an acyl group, and accordinglythe hydrocarbon chain may form part of an alkanoyl group, for examplepalmitoyl, caproyl, lauroyl, myristoyl or stearoyl.

A lipophilic substituent may be conjugated to any amino acid side chainin a compound of the invention. In certain embodiment, the amino acidside chain includes a carboxy, hydroxyl, thiol, amide or amine group,for forming an ester, a sulphonyl ester, a thioester, an amide or asulphonamide with the spacer or lipophilic substituent. For example, thelipophilic substituent may be conjugated to Asn, Asp, Glu, Gln, His,Lys, Arg, Ser, Thr, Tyr, Trp, Cys or Dbu, Dpr or Orn. In certainembodiments, the lipophilic substituent is conjugated to Lys. An aminoacid shown as Lys in any of the formulae provided herein may be replacedby, e.g., Dbu, Dpr or Orn where a lipophilic substituent is added.

In further embodiments of the present invention, alternatively oradditionally, the side-chains of one or more amino acid residues in thecompound of the invention may be conjugated to a polymeric moiety, forexample, in order to increase solubility and/or half-life in vivo (e.g.in plasma) and/or bioavailability. Such modifications are also known toreduce clearance (e.g. renal clearance) of therapeutic proteins andpeptides.

As used herein, “Polyethylene glycol” or “PEG” is a polyether compoundof general formula H—(O—CH2-CH2)n-OH. PEGs are also known aspolyethylene oxides (PEOs) or polyoxyethylenes (POEs), depending ontheir molecular weight PEO, PEE, or POG, as used herein, refers to anoligomer or polymer of ethylene oxide. The three names are chemicallysynonymous, but PEG has tended to refer to oligomers and polymers with amolecular mass below 20,000 g/mol, PEO to polymers with a molecular massabove 20,000 g/mol, and POE to a polymer of any molecular mass. PEG andPEO are liquids or low-melting solids, depending on their molecularweights. Throughout this disclosure, the 3 names are usedindistinguishably. PEGs are prepared by polymerization of ethylene oxideand are commercially available over a wide range of molecular weightsfrom 300 g/mol to 10,000,000 g/mol. While PEG and PEO with differentmolecular weights find use in different applications, and have differentphysical properties (e.g. viscosity) due to chain length effects, theirchemical properties are nearly identical. The polymeric moiety ispreferably water-soluble (amphiphilic or hydrophilic), non-toxic, andpharmaceutically inert. Suitable polymeric moieties include polyethyleneglycols (PEG), homo- or co-polymers of PEG, a monomethyl-substitutedpolymer of PEG (mPEG), or polyoxyethylene glycerol (POG). See, forexample, Int. J. Hematology 68:1 (1998); Bioconjugate Chem. 6:150(1995); and Crit. Rev. Therap. Drug Carrier Sys. 9:249 (1992). Alsoencompassed are peptides that are prepared for purpose of half lifeextension, for example, mono-activated, alkoxy-terminated polyalkyleneoxides (POA's) such as mono-methoxy-terminated polyethyelene glycols(mPEG's); bis activated polyethylene oxides (glycols) or other PEGderivatives are also contemplated. Suitable polymers will varysubstantially by weights ranging from about 70 to about 40,000 or fromabout 200 to about 40,000 are usually selected for the purposes of thepresent invention. Molecular weights from 200 to 2,000 are preferred and200 to 500 are particularly preferred. There are different forms of PEGare also available, depending on the initiator used for thepolymerization process—the most common initiator is a monofunctionalmethyl ether PEG, or methoxypoly(ethylene glycol), abbreviated mPEG.

As used herein, lower-molecular-weight PEGs are also available as pureoligomers, referred to as monodisperse, uniform, or discrete. These areused in certain embodiments of the present invention.

PEGs are also available with different geometries: Branched PEGs havethree to ten PEG chains emanating from a central core group; Star PEGshave 10 to 100 PEG chains emanating from a central core group; Comb PEGshave multiple PEG chains normally grafted onto a polymer backbone. PEGscan also be linear. The numbers that are often included in the names ofPEGs indicate their average molecular weights (e.g. a PEG with n=9 wouldhave an average molecular weight of approximately 400 daltons, and wouldbe labeled PEG 400.

As used herein, “PEGylation” is the act of covalently coupling a PEGstructure to the peptide of the invention, which is then referred to asa “PEGylated peptide”. In some embodiments, the X moiety of formula I,the Y moiety of formula I, the R¹ moiety of formula I, the R² moiety offormula I, or any combination thereof, is PEGylated. In someembodiments, the X′ moiety of formula I′, the Y′ moiety of formula I′,the R¹′ moiety of formula I′, the R²′ moiety of formula I′, or anycombination thereof, is PEGylated. In some embodiments, the X″ moiety offormula I″, the Y″ moiety of formula I″, the R¹″ moiety of formula I″,the R²″ moiety of formula I″, or any combination thereof, is PEGylated.In some embodiments, one or more side chains of an amino acid in thepeptide of formula I, formula I′, or formula I″ is PEGylated. In certainembodiments, the PEG of the PEGylated side chain is a PEG with amolecular weight from about 200 to about 40,000. In some embodiments, aspacer of a peptide of formula I, formula I′, or formula I″ isPEGylated. In certain embodiments, the PEG of a PEGylated spacer isPEG3, PEG4, PEG5, PEG6, PEG7, PEG8, PEG9, PEG10, or PEG11. In certainembodiments, the PEG of a PEGylated spacer is PEG3 or PEG8. In certainembodiments, the PEG of a PEGylated spacer is PEG3 or PEG8.

Other suitable polymeric moieties include poly-amino acids such aspoly-lysine, poly-aspartic acid and poly-glutamic acid (see for exampleGombotz, et al. (1995), Bioconjugate Chem., vol. 6: 332-351; Hudecz, etal. (1992), Bioconjugate Chem., vol. 3, 49-57 and Tsukada, et al.(1984), J. Natl. Cancer Inst., vol. 73: 721-729. The polymeric moietymay be straight-chain or branched. In some embodiments, it has amolecular weight of 500-40,000 Da, for example 500-10,000 Da, 1000-5000Da, 10,000-20,000 Da, or 20,000-40,000 Da.

In some embodiments, a compound of the invention may comprise two ormore such polymeric moieties, in which case the total molecular weightof all such moieties will generally fall within the ranges providedabove.

In some embodiments, the polymeric moiety may be coupled (by covalentlinkage) to an amino, carboxyl or thiol group of an amino acid sidechain. Preferred examples are the thiol group of Cys residues and theepsilon amino group of Lys residues, and the carboxyl groups of Asp andGlu residues may also be involved.

The skilled worker will be well aware of suitable techniques which canbe used to perform the coupling reaction. For example, a PEG moietybearing a methoxy group can be coupled to a Cys thiol group by amaleimido linkage using reagents commercially available from NektarTherapeutics AL. See also WO 2008/101017, and the references citedabove, for details of suitable chemistry. A maleimide-functionalised PEGmay also be conjugated to the side-chain sulfhydryl group of a Cysresidue.

As used herein, disulfide bond oxidation can occur within a single stepor is a two step process. As used herein, for a single oxidation stepthe trityl protecting group is often employed during assembly, allowingdeprotection during cleavage, followed by solution oxidation. When asecond disulfide bond is required one has the option of native orselective oxidation. For selective oxidation requiring orthogonalprotecting groups Acm and Trityl is used as the protecting groups forcysteine. Cleavage results in the removal of one protecting pair ofcysteine allowing oxidation of this pair. The second oxidativedeprotection step of the cysteine protected Acm group is then performed.For native oxidation the trityl protecting group is used for allcysteines, allowing for natural folding of the peptide.

A skilled worker will be well aware of suitable techniques which can beused to perform the oxidation step.

Peptide Dimers

The term “dimer,” as in a peptide dimer, refers to compounds in whichtwo peptide chains are linked, either identical (homo-dimer) ornon-identical (hetero-dimer) through a linking moiety. A cysteine dimeris then two peptides chains linked through the amino acid cysteinedisulfide bond.

In some embodiments, the peptides of the present invention may be activein a dimer conformation or a hetero-dimer conformation, in particularwhen free cysteine residues are present in the peptide. In certainembodiments, this occurs either as a synthesized dimer or, inparticular, when a free cysteine monomer peptide is present and underoxidizing conditions, dimerizes. In some embodiments, the dimer is ahomodimer. In other embodiments, the dimer is a heterodimer.

In certain embodiments, a peptide analogue of the present invention is apeptide dimer comprising a peptide of the invention. In particularembodiments, the peptide dimers comprise a peptide of formula I, apeptide of formula I′, or a peptide of formula I″. In particularembodiments, the peptide dimers comprise two peptides of formula I, twopeptides of formula I′, or two peptides of formula I″. In certainembodiments, the peptide dimers are homodimers. In particularembodiments wherein the peptide dimer comprises a peptide of formula I,X has the formula Ia, Ib, Ic, or Id. In particular embodiments whereinthe peptide dimer comprises a peptide of formula I, Y has the formulaIIa, IIb, IIc, IId, IIe, IIf or IIg. In particular embodiments whereinthe peptide dimer comprises a peptide of formula I′, X′ has the formulaIa′, Ib′, Ic′, or Id′. In particular embodiments wherein the peptidedimer comprises a peptide of formula I′, Y′ has the formula IIa′, IIb′,IIc′, IId′, IIe′, IIf′, or IIg′. In particular embodiments wherein thepeptide dimer comprises a peptide of formula I″, X″ has the formula Ia″,Ib″, Ic″, or Id″. In particular embodiments wherein the peptide dimercomprises a peptide of formula I″, Y″ has the formula IIa″ or IIb″.

In some embodiments, the dimer is between two X groups of formula I, twoX′ groups of formula I′, or two X″ groups of formula I″, e.g., the twopeptides of the dimer are linked through two X groups of formula I, twoX′ groups of formula I′, or two X″ groups of formula I″. In someembodiments, the dimer comprises two X groups of formula I, two X′groups of formula I′, or two X″ groups of formula I″. In someembodiments, the two X groups, X′ groups, or X″ groups in the dimerscomprise the same amino acid residues. In some embodiments, the two Xgroups, X′ groups, or X″ groups in the dimers comprise different aminoacid residues (i.e., each amino acid in each of the two X, X′ or X″groups is independently selected). In some embodiments, the dimer isbetween two Y groups of formula I, two Y groups of formula I′, or two Y″groups of formula I″, e.g., the two peptides of the dimer are linkedthrough two Y groups of formula I, two Y′ groups of formula I′, or twoY″ groups of formula I″. In some embodiments, the dimer comprises two Ygroups of formula I, two Y groups of formula I′, or two Y″ groups offormula I″. In some embodiments, the two Y groups, Y′ groups, or Y″groups in the dimer comprise the same amino acid residues. In someembodiments, the two Y groups, Y′ groups or Y″ groups in the dimercomprise different amino acid residues (i.e., each amino acid in each ofthe Y, Y′ or Y″ groups is independently selected). In some embodiments,a dimer is between an X group of formula I and a Y group of formula I(e.g., the two peptides of the dimer are linked through an X group offormula I and a Y group of formula I), an X′ group of formula I′ and aY′ group of formula I (e.g., the two peptides of the dimer are linkedthrough an X′ group of formula I′ and a Y′ group of formula I′), or anX″ group of formula I″ and a Y″ group of formula I″ (e.g., the twopeptides of the dimer are linked through an X″ group of formula I″ and aY″ group of formula I″).

In particular embodiments, a peptide dimer of the present inventioncomprises a peptide comprising: a peptide sequence set forth in any oneof Tables 5-15 or SEQ ID NOs: 1-334 and 338-375; or a peptide sequencehaving at least 85%, at least 90%, at least 91%, at least 92%, at least93%, at least 94%, at least 95%, at least 96%, at least 97%, at least98%, or at least 99% identity to a peptide sequence set forth in any oneof Tables 5-15 or SEQ ID NOs: 1-334 and 338-375. In particularembodiments, a peptide dimer of the present invention is a homodimercomprising two peptides, each comprising: a peptide sequence set forthin any one of Tables 5-15 or SEQ ID NOs: 1-334 and 338-375; or a peptidesequence having at least 85%, at least 90%, at least 91%, at least 92%,at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identity to a peptide sequence set forth inany one of Tables 5-15 or SEQ ID NOs: 1-334 and 338-375. In particularembodiments, a peptide dimer of the present invention comprises acompound set forth in any one of Tables 5-15. In particular embodiments,a peptide dimer of the present invention is a homodimer comprising twopeptides, each comprising a compound set forth in any one of Tables5-15.

In certain embodiments, the peptide dimers comprise two peptidesdimerized via a disulfide linkage between a cysteine residue present inone of the peptides and a cysteine residue present in the secondpeptide, i.e., an intermolecular disulfide bond between these cysteineresidues.

In certain embodiments, the peptide dimers comprise two peptidesdimerized by covalent attachment of each peptide to a common linkingmoeity, i.e., a linker. A variety of linkers suitable for dimerizing twopeptides are known in the art and commercially available, including,e.g., diethylene glycol (DIG), iminodiacetic acid (IDA), β-Ala-IDA,PEG13, and PEG25. In particular embodiments, peptide dimers include anyof the linking moieties shown below or have any of the structures shownin FIG. 7. In particular embodiments, peptide dimers are dimerized viaboth a linking moiety and a disulphide bond between a cysteine residuein one peptide and a cysteine residue in the other peptide of the dimer.

In certain embodiments, the linking moiety comprises the formula:—NH—R₂₀—NH—, wherein R₂₀ is a lower (C₁₋₂₀) alkyl. In certainembodiments, the linking moiety comprises the formula:—CO—(CH₂)n-(X—(CH₂)m)o-X—(CH₂)pCO—, wherein n is 1-3, m is 1-3, p is1-3, o is 0-24, and X is O or NH. In one embodiment, n, m and p are each2, o is 1-25, X is O.

In certain embodiments, the linking moiety comprises the formula:—NH—(CH₂)α-[O—(CH₂)_(β)]_(γ)—O_(δ)—(CH₂)_(ε)—Y—, wherein α, β and ε areeach integers whose values are independently selected from 1 to 6, δ is0 or 1, γ is an integer selected from 0 to 10, and y is selected from NHor CO, provided that β is 2 when γ is greater than 1.

In various embodiments, the linker is attached to the N-terminal aminoacid of one or both peptides of the dimer, the linker is attached to theC-terminal amino acid of one or both peptides of the dimer, or thelinker is attached to an internal amino acid of one or both peptides ofthe dimer. In one embodiment, the linker is attached to lysine residuesin each of the peptides of the dimer. In particular embodiments, thelinker is not attached to the N-terminal amino acid of one or bothpeptides of the dimer.

In particular embodiments, one or both peptides present in a dimercomprise an amino acid residue that is conjugated (i.e., covalentlyattached) to a lipophilic substituent, including any of those describedherein. In certain embodiments, one or both peptides present in a dimercomprise an amino acid residue that is conjugated to a polymeric moiety,including any of those described herein. In certain embodiments, one orboth of the peptides present in the peptide dimers is conjugated to anacidic compound, e.g., isovaleric acid, isobutyric acid, valeric acid,or the like.

In particular embodiments, a linking moiety present in a dimer isconjugated (i.e., covalently attached) to a lipophilic substituent,including any of those described herein. In certain embodiments, alinking moiety present in a dimer is conjugated to a polymeric moiety,including any of those described herein. In certain embodiments, alinking moiety present in a peptide dimer is conjugated to an acidiccompound, e.g., isovaleric acid, isobutyric acid, valeric acid, or thelike.

Pharmaceutical Compositions

It is to be understood that the inclusion of a peptide analogue or adimer thereof of the invention (i.e., one or more peptide analogues ofthe invention or one or more peptide dimers of the present invention) ina pharmaceutical composition also encompasses inclusion of apharmaceutically acceptable salt or solvate of a peptide analogue or apeptide dimer of the invention.

The invention also provides a pharmaceutical composition comprising apeptide analogue, or a pharmaceutically acceptable salt or solvatethereof, according to the invention. In particular embodiments, theinvention provides a pharmaceutical composition comprising a peptidedimer, or a pharmaceutically acceptable salt or solvate thereof,according to the invention. In particular embodiments, thepharmaceutical compositions further comprise one or morepharmaceutically acceptable carrier, ecxcipient, or vehicle.

The invention also provides a pharmaceutical composition comprising apeptide analogue, or a pharmaceutically acceptable salt or solvatethereof, for treating a variety of conditions, diseases, or disorders asdisclosed herein elsewhere (see, e.g., therapeutic uses, supra). Inparticular embodiments, the invention provides a pharmaceuticalcomposition comprising a peptide dimer, or a pharmaceutically acceptablesalt or solvate thereof, for treating a variety of conditions, diseases,or disorders as disclosed herein elsewhere (see, e.g., therapeutic uses,supra).

The peptide analogues, including the peptide dimers, of the presentinvention may be formulated as pharmaceutical compositions which aresuited for administration with or without storage, and which typicallycomprise a therapeutically effective amount of at least one peptideanalogue of the invention, together with a pharmaceutically acceptablecarrier, excipient or vehicle.

The term “pharmaceutically acceptable carrier” includes any of thestandard pharmaceutical carriers. Pharmaceutically acceptable carriersfor therapeutic use are well known in the pharmaceutical art and aredescribed, for example, in “Remington's Pharmaceutical Sciences”, 17thedition, Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa.,USA, 1985. For example, sterile saline and phosphate-buffered saline atslightly acidic or physiological pH may be used. Suitable pH-bufferingagents may, e.g., be phosphate, citrate, acetate,tris(hydroxymethyl)aminomethane (TRIS),N-tris(hydroxymethyl)methyl-3-aminopropanesulfonic acid (TAPS), ammoniumbicarbonate, diethanolamine, histidine, arginine, lysine or acetate(e.g. as sodium acetate), or mixtures thereof. The term furtherencompasses any carrier agents listed in the US Pharmacopeia for use inanimals, including humans.

A pharmaceutical composition of the invention may be in unit dosageform. In such form, the composition is divided into unit dosescontaining appropriate quantities of the active component or components.The unit dosage form may be presented as a packaged preparation, thepackage containing discrete quantities of the preparation, for example,packaged tablets, capsules or powders in vials or ampoules. The unitdosage form may also be, e.g., a capsule, cachet or tablet in itself, orit may be an appropriate number of any of these packaged forms. A unitdosage form may also be provided in single-dose injectable form, forexample in the form of a pen device containing a liquid-phase (typicallyaqueous) composition. Compositions may be formulated for any suitableroute and means of administration. Pharmaceutically acceptable carriersor diluents include those used in formulations suitable for e.g. oral,intravitreal, rectal, vaginal, nasal, topical, enteral or parenteral(including subcutaneous (SC), intramuscular (IM), intravenous (IV),intradermal and transdermal) administration or administration byinhalation. The formulations may conveniently be presented in unitdosage form and may be prepared by any of the methods well known in theart of pharmaceutical formulation.

Subcutaneous or transdermal modes of administration may be particularlysuitable for the peptide analogues of the invention.

Further embodiments of the invention relate to devices, dosage forms andpackages used to deliver the pharmaceutical formulations of the presentinvention. Thus, at least one peptide analogue or specified portion orvariant in either the stable or preserved formulations or solutionsdescribed herein, can be administered to a patient in accordance withthe present invention via a variety of delivery methods, including SC orIM injection; transdermal, pulmonary, transmucosal, implant, osmoticpump, cartridge, micro pump, or other means appreciated by the skilledartisan as well-known in the art.

Still further embodiments of the invention relate to oral formulationsand oral administration. Formulations for oral administration may relyon the co-administration of adjuvants (e.g. resorcinols and/or nonionicsurfactants such as polyoxyethylene oleyl ether andn-hexadecylpolyethylene ether) to artificially increase the permeabilityof the intestinal walls, and/or the co-administration of enzymaticinhibitors (e.g. pancreatic trypsin inhibitors,diisopropylfluorophosphate (DFF) or trasylol) to inhibit enzymaticdegradation. The active constituent compound of a solid-type dosage formfor oral administration can be mixed with at least one additive, such assucrose, lactose, cellulose, mannitol, trehalose, raffinose, maltitol,dextran, starches, agar, alginates, chitins, chitosans, pectins, gumtragacanth, gum arabic, gelatin, collagen, casein, albumin, synthetic orsemisynthetic polymer, or glyceride. These dosage forms can also containother type(s) of additives, e.g., inactive diluting agent, lubricantsuch as magnesium stearate, paraben, preserving agent such as sorbicacid, ascorbic acid, alpha-tocopherol, antioxidants such as cysteine,disintegrators, binders, thickeners, buffering agents, pH adjustingagents, sweetening agents, flavoring agents or perfuming agents.

Dosages

A typical dosage of a peptide analogue, e.g., a peptide or a dimer ofthe invention, as employed in the context of the present invention maybe in the range from about 0.0001 to about 100 mg/kg body weight perday, such as from about 0.0005 to about 50 mg/kg body weight per day,such as from about 0.001 to about 10 mg/kg body weight per day, e.g.from about 0.01 to about 1 mg/kg body weight per day, administered inone or more doses, such as from one to three doses. As already indicatedto some extent above, the exact dosage employed will depend, inter alia,on: the nature and severity of the disease or disorder to be treated;the sex, age, body weight and general condition of the subject to betreated; possible other, concomitant, disease or disorder that isundergoing or is to undergo treatment; as well as other factors thatwill be known to a medical practitioner of skill in the art.

A peptide analogue, e.g., a peptide or a dimer, of the invention may beadministered continuously (e.g. by intravenous administration or anothercontinuous drug administration method), or may be administered to asubject at intervals, typically at regular time intervals, depending onthe desired dosage and the pharmaceutical composition selected by theskilled practitioner for the particular subject. Regular administrationdosing intervals include, e.g., once daily, twice daily, once every two,three, four, five or six days, once or twice weekly, once or twicemonthly, and the like.

Such regular peptide analogue, peptide, or dimer administration regimensof the invention may, in certain circumstances such as, e.g., duringchronic long-term administration, be advantageously interrupted for aperiod of time so that the medicated subject reduces the level of orstops taking the medication, often referred to as taking a “drugholiday.” Drug holidays are useful for, e.g., maintaining or regainingsensitivity to a drug especially during long-term chronic treatment, orto reduce unwanted side-effects of long-term chronic treatment of thesubject with the drug. The timing of a drug holiday depends on thetiming of the regular dosing regimen and the purpose for taking the drugholiday (e.g., to regain drug sensitivity and/or to reduce unwanted sideeffects of continuous, long-term administration). In some embodiments,the drug holiday may be a reduction in the dosage of the drug (e.g. tobelow the therapeutically effective amount for a certain interval oftime). In other embodiments, administration of the drug is stopped for acertain interval of time before administration is started again usingthe same or a different dosing regimen (e.g. at a lower or higher doseand/or frequency of administration). A drug holiday of the invention maythus be selected from a wide range of time-periods and dosage regimens.An exemplary drug holiday is two or more days, one or more weeks, or oneor more months, up to about 24 months of drug holiday. So, for example,a regular daily dosing regimen with a peptide, a peptide analogue, or adimer of the invention may, for example, be interrupted by a drugholiday of a week, or two weeks, or four weeks, after which time thepreceding, regular dosage regimen (e.g. a daily or a weekly dosingregimen) is resumed. A variety of other drug holiday regimens areenvisioned to be useful for administering the peptides, the dimers, andthe peptide analogues of the invention.

Thus, the peptide analogue, peptide, or dimer may be delivered via anadministration regime which comprises two or more administration phasesseparated by respective drug holiday phases.

During each administration phase, the peptide analogue, peptide, ordimer is administered to the recipient subject in a therapeuticallyeffective amount according to a pre-determined administration pattern.The administration pattern may comprise continuous administration of thedrug to the recipient subject over the duration of the administrationphase. Alternatively, the administration pattern may compriseadministration of a plurality of doses of the peptide analogue to therecipient subject, wherein said doses are spaced by dosing intervals.

A dosing pattern may comprise at least two doses per administrationphase, at least five doses per administration phase, at least 10 dosesper administration phase, at least 20 doses per administration phase, atleast 30 doses per administration phase, or more.

Said dosing intervals may be regular dosing intervals, which may be asset out above, including once daily, twice daily, once every two, three,four, five or six days, once or twice weekly, once or twice monthly, ora regular and even less frequent dosing interval, depending on theparticular dosage formulation, bioavailability, and pharmacokineticprofile of the peptide analogue the peptide, or the peptide dimer of thepresent invention.

An administration phase may have a duration of at least two days, atleast a week, at least 2 weeks, at least 4 weeks, at least a month, atleast 2 months, at least 3 months, at least 6 months, or more.

Where an administration pattern comprises a plurality of doses, theduration of the following drug holiday phase is longer than the dosinginterval used in that administration pattern. Where the dosing intervalis irregular, the duration of the drug holiday phase may be greater thanthe mean interval between doses over the course of the administrationphase. Alternatively the duration of the drug holiday may be longer thanthe longest interval between consecutive doses during the administrationphase.

The duration of the drug holiday phase may be at least twice that of therelevant dosing interval (or mean thereof), at least 3 times, at least 4times, at least 5 times, at least 10 times, or at least 20 times that ofthe relevant dosing interval or mean thereof.

Within these constraints, a drug holiday phase may have a duration of atleast two days, at least a week, at least 2 weeks, at least 4 weeks, atleast a month, at least 2 months, at least 3 months, at least 6 months,or more, depending on the administration pattern during the previousadministration phase.

An administration regime comprises at least 2 administration phases.Consecutive administration phases are separated by respective drugholiday phases. Thus the administration regime may comprise at least 3,at least 4, at least 5, at least 10, at least 15, at least 20, at least25, or at least 30 administration phases, or more, each separated byrespective drug holiday phases.

Consecutive administration phases may utilise the same administrationpattern, although this may not always be desirable or necessary.However, if other drugs or active agents are administered in combinationwith a peptide analogue, a peptide or a peptide dimer of the invention,then typically the same combination of drugs or active agents is givenin consecutive administration phases. In certain embodiments, therecipient subject is human.

Devices and Kits

In some embodiments, the invention relates to a device comprising one ormore peptides, peptide analogues, peptide dimersor pharmaceuticallyacceptable salts or solvates thereof of the invention, for delivery ofthe compound of the present invention to a subject. Thus, one or morepeptide analogues, peptides, dimers, or pharmaceutically acceptablesalts or solvates thereof can be administered to a patient in accordancewith the present invention via a variety of delivery methods includingintravenous, subcutaneous, intramuscular, or intraperitoneal injection;oral administration, transdermally, by pulmonary or transmucosaladministration, by implant or osmotic pump, by cartridge or micro pump,or by other means appreciated by the skilled artisan, as well-known inthe art.

In some embodiments, the invention relates to a kit comprising one ormore peptide analogues or pharmaceutically acceptable salts or solvatesthereof of the invention. In some embodiments, the invention relates toa kit comprising one or more peptide dimer of the present invention, orpharmaceutically acceptable salts or solvates thereof. In otherembodiments, the kit comprises one or more pharmaceutical compositionscomprising one or more peptide analogues or pharmaceutically acceptablesalts or solvates thereof. In certain embodiments, the kit furthercomprises packaging or instructions for use. In other embodiments, thekit comprises one or more pharmaceutical compositions comprising one ormore peptide dimer of the present invention, or pharmaceuticallyacceptable salts or solvates thereof In certain embodiments, the kitfurther comprises packaging or instructions for use.

Combination Therapy

As noted above, it will be understood that reference in the following toa peptide analogue of the invention (e.g., the compounds listed in anyone of Tables 5-15, for example compounds 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 65, 66, 67, 68,69, 70, 71, 73, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88,89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105,106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 117, 118, 119, 120,121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134,135, 136, 137, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149,150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163,164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 176, 177, 178, 179,180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193,194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207,208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221,222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235,236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249,250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263,264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291,293, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309,310, 355, 356, 357, 358, 359, 360, 361 or dimers thereof, e.g., any oneof the peptide dimers disclosed in Tables 12-15, for example compounds311-353 also extends to a pharmaceutically acceptable salt or solvatethereof, as well as to a composition comprising more than one differentpeptide, peptide analogue, or peptide dimer of the invention.

In certain embodiments, a peptide analogue or a peptide dimer of theinvention may have some benefit if administered in combination with aniron chelator, such as Deferoxamine and Deferasirox (Exjade™)

EXAMPLES

The following examples demonstrate certain specific embodiments of thepresent invention. The following examples were carried out usingstandard techniques that are well known and routine to those of skill inthe art, except where otherwise described in detail. It is to beunderstood that these examples are for illustrative purposes only and donot purport to be wholly definitive as to conditions or scope of theinvention. As such, they should not be construed in any way as limitingthe scope of the present invention.

Abbreviations

-   DCM: dichloromethane-   DMF: N,N-dimethylformamide-   NMP: N-methylpyrolidone-   HBTU: O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium    hexafluorophosphate-   HATU: 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium    hexafluorophosphate-   DCC: Dicyclohexylcarbodiimide-   NHS: N-hydoxysuccinimide-   DIPEA: diisopropylethylamine-   EtOH: ethanol-   Et2O: diethyl ether-   Hy: hydrogen-   TFA: trifluoroacetic acid-   TIS: triisopropylsilane-   ACN: acetonitrile-   HPLC: high performance liquid chromatography-   ESI-MS: electron spray ionization mass spectrometry-   PBS: phosphate-buffered saline-   Boc: t-butoxycarbonyl-   Fmoc: Fluorenylmethyloxycarbonyl-   Acm: acetamidomethyl-   IVA: Isovaleric acid (or Isovaleryl)-   K( ): In the peptide sequences provided herein, wherein a compound    or chemical group is presented in parentheses directly after a    Lysine residue, it is to be understood that the compound or chemical    group in the parentheses is a side chain conjugated to the Lysine    residue. So, e.g., but not to be limited in any way, K(PEG8)    indicates that a PEG8 moiety is conjugated to a side chain of this    Lysine. For a few non-limiting examples of such a conjugated    Lysines, please see, e.g., compounds 54 and 90.-   Palm: Indicates conjugation of a palmitic acid (palmitoyl).

As used herein “C( )” refers to a cysteine residue involved in aparticular disulfide bridge. For example, in Hepcidin, there are fourdisulfide bridges: the first between the two C(1) residues; the secondbetween the two C(2) residues; the third between the two C(3) residues;and the fourth between the two C(4) residues. Accordingly, in someembodiments, the sequence for Hepcidin is written as follows:Hy-DTHFPIC(1)IFC(2)C(3)GC(2)C(4)HRSKC(3)GMC(4)C(1)KT-OH (SEQ ID NO:335);and the sequence for other peptides may also optionally be written inthe same manner.

The following examples are provided to illustrate certain embodiments ofthe invention and are not intended to limit the scope of the invention.

Example 1 Synthesis of Compounds

Unless otherwise specified, reagents and solvents employed in thefollowing were available commercially in standard laboratory reagent oranalytical grade, and were used without further purification.

Procedure for Solid-Phase Synthesis of Peptides

Illustrative compounds of the invention (e.g., Compound No. 2) werechemically synthesized using optimized 9-fluorenylmethoxy carbonyl(Fmoc) solid phase peptide synthesis protocols. For C-terminal amides,rink-amide resin was used, although wang and trityl resins were alsoused to produce C-terminal acids. The side chain protecting groups wereas follows: Glu, Thr and Tyr: O-tButyl; Trp and Lys: t-Boc(t-butyloxycarbonyl); Arg:N-gamma-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; His, Gln,Asn, Cys: Trityl. For selective disulfide bridge formation, Acm(acetamidomethyl) was also used as a Cys protecting group. For coupling,a four to ten-fold excess of a solution containing Fmoc amino acid, HBTUand DIPEA (1:1:1.1) in DMF was added to swelled resin [HBTU:O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate;DIPEA: diisopropylethylamine; DMF: dimethylformamide]. HATU(O-(7-azabenzotriazol-1-yl)-1,1,3,3,-tetramethyluroniumhexafluorophosphate) was used instead of HBTU to improve couplingefficiency in difficult regions. Fmoc protecting group removal wasachieved by treatment with a DMF, piperidine (2:1) solution.

Procedure for Cleavage of Peptides Off Resin

Side chain deprotection and cleavage of the peptides of the invention(e.g., Compound No. 2) was achieved by stirring dry resin in a solutioncontaining trifluoroacetic acid, water, ethanedithiol andtri-isopropylsilane (90:5:2.5:2.5) for 2 to 4 hours. Following TFAremoval, peptide was precipitated using ice-cold diethyl ether. Thesolution was centrifuged and the ether was decanted, followed by asecond diethyl ether wash. The peptide was dissolved in an acetonitrile,water solution (1:1) containing 0.1% TFA (trifluoroacetic acid) and theresulting solution was filtered. The linear peptide quality was assessedusing electrospray ionisation mass spectrometry (ESI-MS).

Procedure for Purification of Peptides

Purification of the peptides of the invention (e.g., Compound No. 2) wasachieved using reverse-phase high performance liquid chromatography(RP-HPLC). Analysis was performed using a C18 column (3 μm, 50×2 mm)with a flow rate of 1 mL/min. Purification of the linear peptides wasachieved using preparative RP-HPLC with a C18 column (5 μm, 250×21.2 mm)with a flow rate of 20 mL/min. Separation was achieved using lineargradients of buffer B in A (Buffer A: Aqueous 0.05% TFA; Buffer B:0.043% TFA, 90% acetonitrile in water).

Procedure for Oxidation of Peptides

Method A (Single disulfide oxidation). Oxidation of the unprotectedpeptides of the invention (e.g., Compound No. 2) was achieved by addingdrop-wise iodine in MeOH (1 mg per 1 mL) to the peptide in a solution(ACN: H₂O, 7:3, 0.5% TFA). After stirring for 2 min, ascorbic acidportion wise was added until the solution was clear and the sample wasimmediately loaded onto the HPLC for purification.

Method B (Selective oxidation of two disulfides). When more than onedisulfide was present (e.g., Compound 30), selective oxidation was oftenperformed. Oxidation of the free cysteines was achieved at pH 7.6 NH₄CO₃solution at 1 mg/10 mL of peptide. After 24 h stirring and prior topurification the solution was acidified to pH 3 with TFA followed bylyophilization. The resulting single oxidized peptides (with ACMprotected cysteines) were then oxidized/selective deprotection usingiodine solution. The peptide (1 mg per 2 mL) was dissolved in MeOH/H₂0,80:20 iodine dissolved in the reaction solvent was added to the reaction(final concentration: 5 mg/mL) at room temperature. The solution wasstirred for 7 minutes before ascorbic acid was added portion wise untilthe solution is clear. The solution was then loaded directly onto theHPLC.

Method C (Native oxidation). When more than one disulfide was presentand when not performing selective oxidations, native oxidation wasperformed (e.g., this method was used for Compound 19). Native oxidationwas achieved with 100 mM NH4CO3 (pH7.4) solution in the presence ofoxidized and reduced glutathione (peptide/GSH/GSSG, 1:100:10 molarratio) of (peptide: GSSG: GSH, 1:10, 100). After 24 h stirring and priorto RP-HPLC purification the solution was acidified to pH 3 with TFAfollowed by lyophilization.

Procedure of Cysteine oxidation to produce dimers. Oxidation of theunprotected peptides of the invention (e.g., Compound No. 1) wasachieved by adding drop-wise iodine in MeOH (1 mg per 1 mL) to thepeptide in a solution (ACN: H2O, 7:3, 0.5% TFA). After stirring for 2min, ascorbic acid portion wise was added until the solution was clearand the sample was immediately loaded onto the HPLC for purification.

Procedure for Dimerization. Glyxoylic acid, IDA, or Fmoc-β-Ala-IDA waspre-activated as the N-hydoxysuccinimide ester by treating the acid (1equiv) with 2.2 eq of both N-hydoxysuccinimide (NHS) and dicyclohexylcarbodiimide (DCC) in NMP (N-methyl pyrolidone) at a 0.1 M finalconcentration. For the PEG13 and PEG25 linkers, these chemical entitieswere purchased pre-formed as the activated succinimide ester. Theactivated ester ˜0.4 eq was added slowly to the peptide in NMP (1 mg/mL)portionwise. The solution was left stirring for 10 min before 2-3additional aliquots of the linker ˜0.05 eq were slowly added. Thesolution was left stirring for a further 3 h before the solvent wasremoved under vaccuo and the residue was purified by reverse phase HPLC.An additional step of stirring the peptide in 20% piperidine in DMF(2×10 min) before an additional reverse phase HPLC purification wasperformed.

One of skill in the art will appreciate that standard methods of peptidesynthesis may be used to generate the compounds of the invention.

Example 2 Activity Assays Methodology

The designed peptides were tested in vitro for induction of degradationof the human ferroportin protein.

The cDNA encoding the human ferroportin (SLC40A1) was cloned from a cDNAclone from Origene (NM_014585). The DNA encoding the ferroportin wasamplified by PCR using primers also encoding terminal restriction sitesfor subcloning, but without the termination codon. The ferroportinreceptor was subcloned into a mammalian GFP expression vector containinga neomycin (G418) resistance marker in such that the reading frame ofthe ferroportin was fused in frame with the GFP protein. The fidelity ofthe DNA encoding the protein was confirmed by DNA sequencing. HEK293cells were used for transfection of the ferroportin-GFP receptorexpression plasmid. The cells were grown according to standard protocolin growth medium and transfected with the plasmids using Lipofectamine(manufacturer's protocol, Invitrogen). The cells stably expressingferroportin-GFP were selected using G418 in the growth medium (in thatonly cells that have taken up and incorporated the cDNA expressionplasmid survive) and sorted several times on a Cytomation MoFlo™ cellsorter to obtain the GFP-positive cells (488 nm/530 nm). The cells werepropagated and frozen in aliquots.

To determine compound activity on the human ferroportin, the cells wereincubated in 96 well plates in standard media, without phenol red.Compound was added to desired final concentration for at least 18 hoursin the incubator. Following incubation, the remaining GFP-fluorescencewas determined either by whole cell GFP fluorescence (Envision platereader, 485/535 filter pair), or by Beckman Coulter Quanta™ flowcytometer (express as Geometric mean of fluorescence intensity at 485nm/525 nm). Compound was added to desired final concentration for atleast 18 hours but no more than 24 hours in the incubator.

Reference compounds included native Hepcidin, Mini-Hepcidin, andR1-Mini-Hepcidin, which is an analog of mini-hepcidin. The “RI” inRI-Mini-Hepcidin refers to Retro Inverse. A retro inverse peptide is apeptide with a reversed sequence in all D amino acids. An example isthat Hy-Glu-Thr-His-NH2 becomes Hy-DHis-DThr-Dglu-NH2. The EC50 of thesereference compounds for ferroportin degradation was determined accordingto the activity assay described above. These peptides served as controlstandards for many of the subsequence studies.

TABLE 4 Reference compounds SEQ ID Name Sequence No. EC50 (nM) HepcidinHy- 335 169 DTHFPIC(1)IFC(2)C(3)GC(2)C(4)HRSKC (3)GMC(4)C(1)KT-OH Mini-Hy-DTHFPICIF-NH₂ 336 712 Hepcidin 1-9 RI-MiniHy-DPhe-DIle-DCys-DIle-DPro-DPhe- 337 >10 μM Hepcidin DHis-DThr-DAsp-NH₂

To determine whether a given peptide modifies the internalization anddegradation of endogenous ferroportin, the protein levels and cellulardistribution of ferroportin in hepatocytes and macrophages treated withthe peptide may be assayed using Western blotting, immunohistochemistryand ferroportin antibodies known in the art.

Example 3 Cysteine Replacement Scan of Mini-Hepcidin

Previous studies indicate that the N-terminal segment of Hep25 isimportant for its hepcidin activity and is likely to form the interfacewith ferroportin. Furthermore, it was thought that Cys in the 7^(th)position is critical for activity. Disulfide bonds can act bystructural, catalytic or by functional means. It is postulated thatHepcidin binds to Ferroportin through a disulphide linkage whichsubsequently internalizes the receptor. A closer inspection of hepcidinreveled that there are 4 disulfides present and that, any one of thesecysteine might be responsible for binding to ferroportin. As such, thefree thiol of ferroportin possesses a “functional, allosteric bond”equivalent. In order to more thoroughly understand the structureactivity relationship with respect to the position of the cysteineswithin Hepcidin, we performed a cysteine scan up to the 15^(th) residueof a mini-hepcidin peptide and we analyzed the peptides for theirability to exhibit hepcidin activity. Peptides were synthesized usingthe methods described in Example 1, and their potency for ferroportindegradation was tested as described in Example 2. Results of this studyare shown in Table 5, with potency indicated by EC50 values.

TABLE 5 Cysteine replacement scan of Mini-Hepcidin derivatives SEQCompound ID EC50 Number No. Sequence (nM) (n > 3) 269 292 DTHFPIAIFAAGIC I-NH₂ Not active 270 293 DTHFPIAIFAAI C I-NH₂ Not active 271 294DTHFPIAIFAI C I-NH₂ Not active 272 295 DTHFPIAIFI C I-NH₂ Not active 273296 DTHFPIAII C I-NH₂ Not active 274 297 DTHFPIAI C I-NH₂ Not active 275298 DTHFPII C I-NH₂ Not active Mini-Hepcidin 336 Hy-DTHFPI C IF-NH₂ 712nM 1-9   1 28 DTHFP C IIF-NH₂ 133 nM 276 299 DTHI C IAIF-NH₂ Not active277 300 DTH C PIAIF-NH₂ Not active Inactive = Not active at 30 μM and/orlowest dose

Altering the position of the cysteine ablated activity for most of thepeptides that were tested; however these data surprisingly demonstratedthat Compound 1 is active despite having a Cysteine at the 6^(th)position. FIG. 1 shows a comparison of the dose response curves forCompound 1, as compared to Hepcidin, and the Mini-Hepcidin control.These data clearly demonstrate that Compound 1 has similar in-vitropotency as Hepcidin.

Example 4 Ala Scans of Compound 1 Identified in Cysteine Scan

To validate the results from Example 3, an Ala scan was performed onCompound 1. Peptides were synthesized as described in Example 1, andthey were tested for activity as described in Example 2. The results ofthis study are shown in Table 6. By comparing this result with knownstructure activity relationships with hepcidin and other mini-hepcidinanalogs, we have increased potency. Moreover, these data clearlydemonstrate the importance of several residues for activity. Conversly,these date also identify a number of residues that can be modifiedwithout ablating activity.

TABLE 6 Alanine scan of Compound 1 SEQ Compound ID Number No. SequenceEC50 (nM) (n > 3) 1 28 DTHFPCIIF-NH₂ 133 nM 278 301 DTHFPCII A -NH₂  >1μM 51 78 DTHFPCI A F-NH₂ 382 nM 279 302 DTHFPC A IF-NH₂  >1 μM 280 303DTHF A CIIF-NH₂  >1 μM 282 305 DTH A PCIIF-NH₂ Not active 283 306 DT AFPCIIF-NH₂ 739 nM 52 79 D A HFPCIIF-NH₂ 388 nM 284 307 A THFPCIIF-NH₂ >1 μM 281 304 DTHF-[(D)- AlA ]-CIIF- Not active NH₂

Example 5 Analysis of Peptide Activities In Vitro

Based in part on the structure activity relationships (SAR) determinedfrom the results of the experiments described in Examples 3 and 4, avariety of Hepcidin-like peptides of the present invention weresynthesized using the method described in Example 1, and in vitroactivity was tested as described in Example 2. Reference compounds(shown in Table 4) included native Hepcidin, Mini-Hepcidin, andR1-Mini-Hepcidin. EC50 values of the peptides are shown in summary Table7.

TABLE 7 In vitro activity of Hepcidin analog peptides SEQ ID Potency No.No. Sequence EC₅₀ (nM) 1 28 Hy-DTHFPCIIF-NH₂ 133 2 29 Isovalericacid-DTHFPICIFGPRSKGWVC-NH₂ 5 3 30 Isovalericacid-DTHFPCIIFGPRSRGWVCK-NH₂ 15 4 31 Isovalericacid-DTHFPCIIFGPRSKGWVC-NH₂ 19 5 32[Ida]-TH-[Dpa]-[bhPro]-ICIFGPRSKGWVCM-NH₂ 17 6 33 Isovalericacid-DTHFPCIFFGPRSKGWVCK-NH₂ 23 7 34 Isovalericacid-DTHFPCIIFGPRSKGWTCK-NH₂ 24 8 35[Ida]-TH-[Dpa]-[bh-Pro]-CIIFGPRSRGWVCK-NH₂ 29 9 36 Isovalericacid-DTHFPCIKFGPRSKGWVCK-NH₂ 32 10 37 Isovalericacid-DTHFPCIQFGPRSKGWVCK-NH₂ 35 11 38 Isovalericacid-DTHFPCIIFGPRSKGWVCK-NH₂ 9 12 39 Hy-DTHFPIC₁IFVC₂GHRSIC₂YRRC₁R-NH₂77 13 40 Isobutyric acid-DTHFPIC₁IFVC₂HRSKGC₂YRRC₁R-NH₂ 63 14 41Hy-DTHFPIC₁IFVC₂HRSKGC₂YRAC₁-NH₂ 69 15 42 Isovalericacid-DTHFPCIEFGPRSKGWVCK-NH₂ 79 16 43 Hy-DTHFPICIFGPRAKGWVCM-NH₂ 88 1744 Isobutyric acid-DTHFPIC₁IFVC₂HRSKGC₂YRRC₁R-NH₂ 93 18 45Hy-DTHFPICIFGPRSKGWVCM-NH₂ 125 19 46 Hy-DTHFPIC₁IFVC₂HRSKGC₂YRRC₁R-NH₂140 20 47 Hy-DTHFPICIFGPRSRGWVCK-NH₂ 101 21 48Hy-DTHFPCIIFGPRSKGWVCM-NH₂ 46 22 49 Hy-DTHFPICIFAPRSKGWVCM-NH₂ 9430 2350 Hy-DTHFPICIFGPRSKGWVCM-OH 131 24 51 Hy-DTHFPCIQF-NH₂ 138 25 52Hy-DTHFPIC₁IFVC₂GHRSKGC₂YRRC₁R-NH₂ 144 26 53 Hy-DTHFAICIFGPRSKGWVCM-NH₂147 27 54 Hy-DTHFPICIFGPHRSKGWVCM-NH₂ 149 28 55Hy-DTHFPICIFGPRAKGWVCM-NH₂ 88 29 56 Hy-DTHFPACIFGPRSKGWVCM-NH₂ 157 30 57Hy-DTHFPC₁IIFVC₂HRPKGC₂YRRVC₁R-NH₂ 173 31 58 Hy-DTHFPICIFGPRSKAWVCM-NH₂175 32 59 Hy-DTHFPIC₁IFVC₂GHRGKGC₂YRRC₁R-NH₂ 182 33 60Hy-ATHFPICIFGPRSKGWVCM-NH₂ 184 34 61 Hy-DTHFPICIFGPASKGWVCM-NH₂ 206 3562 Hy-DTHFPIC₁IFVC₂HRSKGC₂YARC₁-NH₂ 214 36 63 Ac-DTHFPICIFGPRSKGWVCM-NH₂239 37 64 Hy-DTHFPICIFGPRSAGWVCM-NH₂ 239 38 65Hy-DTHAPICIFGPRSKGWVCM-NH₂ 254 39 66 Hy-DTHFPIC₁IFVC₂HRSKGC₂YRRC₁-NH₂256 40 67 pGlu-THFPIC₁IFVC₂HRSKGC₂YRRC₁R-NH₂ 260 41 68Ac-DTHFPICIFKPRSKGWVCM-NH₂ 262 42 69 Hy-DTHFPIC₁IFVC₂GHRSKGC₂YMRC₁KT-NH₂265 43 70 Hy-DAHFPICIFGPRSKGWVCM-NH₂ 265 44 71Hy-DTHFPIC₁IFVC₂YRGIC₂YRRC₁R-NH₂ 269 45 72 Ac-DTHFPICIFGPRSKGWVCM-NH₂272 46 73 Hy-[bhAsp]-THFPICIFGPRSKGWVC-NH₂ 274 47 74Hy-DTHFPICIFGPRSKGWACM-NH₂ 313 48 75[Ida]-TH-[Dpa]-[bhPro]-RCR-[bhPhe]-GPRSKGWVCM- 331 NH₂ 49 76Hy-DTHFPCIRF-NH₂ 334 50 77 Isovaleric acid-THFPCIIFGPRSKGWVCM-NH₂ 345 5178 Hy-DTHFPCIAF-NH₂ 382 52 79 Hy-DAHFPCIIF-NH₂ 388 53 80Hy-DTHFPIC₁IFVC₂HRPKGC₂YRRC₁P-NH2 393 54 81Ac-DTHFPICIFKPRS-K(PEG8)-GWVCM-NH₂ 479 55 82 Hy-DTHFPCIIFK-NH₂ 419 56 83Hy-DTHFPCIFF-NH₂ 441 57 84 Hy-DTHFPICIFGPRSK-K(PEG8)-WVCM-NH₂ 462 58 85Ac-DTHFPICIFGPRSKKWVCM-NH₂ 472 59 86 Hy-DTHFPIC₁IFC₂PWGMC₂C₁K-NH2 495 6087 Hy-DTAFPICIFGPRSKGWVCM-NH₂ 498 65 88Hy-DTHFPIC₁IFVC₂YRGIC₁YMRC₂KT-NH₂ 763 66 89 Hy-DTHFPICIFGPRSKGAVCM-NH₂520 67 90 Hy-DTHFPICIAGPRSKGWVCM-NH₂ 2466 68 91Hy-DTHFPICAFGPRSKGWVCM-NH₂ >10 μM  69 92 Hy-DTHFPIAIFGPRSKGWVAM-NH₂Inactive 70 93 Hy-DTHFPCRRFGPRSKGWVC-NH₂ Inactive 71 94[Ida]-THF-[bh-Pro]-CRR-[bh-Phe]-GPRSKGWVC-NH₂ N/A 73 96Hy-DTHFPC₁IIFVC₂HRSKGC₂YWAVC₁-NH₂ 2640 74 97Hy-DTHFP-(D)Cys₁-IIFVC₂HRSKGC₂YWAV-(D)Cys₁- 356 F-NH₂ 75 98Hy-DTHFPC₁IIFVC₂HRSKGC₂YWAVC₁FW-NH₂ Not Tested 76 99Ac-DTHFPICIF-K(PEG8)-PRSKGWVCM-NH₂ 610 78 101Hy-DTH-[Dpa]-PCIIFGPRSRGWVCK-NH₂ >1 μM 79 102Hy-DTHF-[bh-Pro]-CIIFGPRSRGWVCK-NH₂ >1 μM 80 103Hy-DTHFPCIIFGPRSRGWRCK-NH₂ >1 μM 81 104 Hy-DTHFPCIRFGPRSRGWVCK-NH₂ >1 μM82 105 Hy-DTHFPCIRFGPRSRGWRCK-NH₂ >1 μM 83 106Hy-DTHFPCIIFGPRSRGWVCK-NH₂ >1 μM 84 107 Hy-DTHFPCIIFGPRSRGVCK-NH₂ >1 μM85 108 Hy-DTHFPCIYFGPRSKGWVCK-NH₂ 705 86 109Hy-DTHFPCIIFGPRSKGWVCK-NH₂ >1 μM 87 110 Hy-DTHFPCIIFGPRARGWVCK-NH₂ >1 μM88 111 Octanoic acid-DTHFPCIIFGPRSRGWVCK-NH₂ >1 μM 89 112Palm-PEG11-DTHFPCIIFGPRSRGWVCK-NH₂ >1 μM 90 113 Ac-DTHFPICIF-K(2KPEG)-PRSKGWVCK-NH₂ 107 91 114 Hy-DTHFPCIIFGPRSKGWKCK-NH₂ Not Tested 92115 Hy-DTHFPCIKFGPRSKGWKCK-NH₂ Not Tested 93 116 Isovalericacid-DTHFPCLIFGPRSKGWVCK-NH₂ 19 94 117 Isovalericacid-DTHFPCVIFGPRSKGWVCK-NH₂ 41 95 118 Isovalericacid-DTHFPCSIFGPRSKGWVCK-NH₂ 78 96 119 Isovalericacid-DTHFPCQIFGPRSKGWVCK-NH₂ 157 97 120 Hy-THFPCIIFGPRSKGWVCK-NH₂Inactive 98 121 Isovaleric acid-THFPCIIFGPRSKGWVCK-NH₂ Inactive 99 122Hy-HFPCIIFGPRSKGWVCK-NH₂ Inactive 100 123 Isovalericacid-HFPCIIFGPRSKGWVCK-NH₂ Inactive 101 124Hy-DTHFPCISFGPRSKGWVCK-NH₂ >1 μM 102 125 Hy-DTHFPCIKFGPRSKGWVCK-NH₂ >1μM 103 126 Hy-EDTHFPCIIFGPRSKGWVCK-NH₂ >1 μM 105 128 Isovalericacid-DTHFPCIIFEPRSKGWVCK-NH₂ 10 106 129 Isovalericacid-DTHFPCIIFSPRSKGWVCK-NH₂ 44 107 130 Isovalericacid-DTHFSCIIFGPRSKGWVCK-NH₂ 50 108 131 Octanoicacid-PEG11-DTHFPCIIFGPRSRGWVCK-NH₂ >1 μM 109 132 Isobutyricacid-PEG11-DTHFPCIIFGPRSRGWVCK-NH₂ >1 μM 110 133[Ida]-THFPCIIFGPRSRGWVCK-NH₂ >300 nM   111 134 Isovalericacid-DTHFPCIIFGPKSKGWVCK-NH₂ 12 112 135 Isovalericacid-DTHFPCIKFGPKSKGWVCK-NH₂ 15 113 136 Isovalericacid-DTHFPCIIFGPRSKGWCK-NH₂ 15 114 137 Isovalericacid-DTHFPCIIFGPRSKGVC-NH₂ 18 115 138 Isovalericacid-DTHFPCIIFGPRSKGCK-NH₂ 21 117 140 Isovalericacid-DTHFPC-[Dapa]-IFGPRSKGWDCK-NH₂ 65 118 141 Isovalericacid-DTHFPCI-[Dapa]-FGPRSKGWDCK-NH₂ 17 119 142 Isovalericacid-DTHFPC-[Dapa]-IFGPRSKGWECK-NH₂ 151 120 143 Isovalericacid-DTHFPCI-[Dapa]-FGPRSKGWECK-NH₂ 15 121 144 Isovalericacid-DTHFPCIKFGPRSKGWECK-NH₂ 14 122 145 Isovalericacid-DTHFGCIIFGPRSKGWVCK-NH₂ 57 123 146 Hy-DTHFGCIIFGPRSKGWVCK-NH₂Inactive 124 147 Isovaleric acid-DTHFRCIIFGPRSKGWVCK-NH₂ 106 125 148Hy-DTHFRCIIFGPRSKGWVCK-NH₂ Inactive 126 149 Isovalericacid-DTHF-[Sarc]-CIIFGPRSKGWVCK-NH₂ 31 127 150Hy-DTHF-[Sarc]-CIIFGPRSKGWVCK-NH₂ Inactive 128 151 Isovalericacid-DTHF-[β-Ala]-CIIFGPRSKGWVCK-NH₂ 264 129 152Hy-DTHF-[β-Ala]-CIIFGPRSKGWVCK-NH₂ Inactive 130 153 Isovalericacid-DTHFKCIIFGPRSKGWVCK-NH₂ 150 131 154 Hy-DTHFKCIIFGPRSKGWVCK-NH₂Inactive 132 155 Hy-THFPCIIFGPRSKGWVCM-NH₂ >1 μM 133 156Hy-HFPCIIFGPRSKGWVCM-NH₂ >1 μM 134 157 Isovalericacid-HFPCIIFGPRSKGWVCM-NH₂ >1 μM 135 158 Hy-DTHFPCISFGPRSKGWVCM-NH₂ 545136 159 Hy-DTHFPCIKFGPRSKGWVCM-NH₂ 669 137 160Hy-EDTHFPCIIFGPRSKGWVCM-NH₂ 873 139 162 Hy-DTHFPCIIFEPRSKGWVCM-NH₂ N/A140 163 Isovaleric acid-DTHFKCIEFGPRSKGWVCK-NH₂ >1 μM 141 164 Isovalericacid-DTHFPCIIFGPRSKGWACK-NH₂ 11 142 165 Isovalericacid-DTHFPCIIFEPRSKGWVCK-NH₂ 9 143 166 Isovalericacid-DTHFPCIIFGPRSKGWVCKKKK-NH₂ 24 144 167 Isovalericacid-DTHFPCIIFEPRSKGWVCKKKK-NH₂ 15 145 168 Isovalericacid-DTHFPCIIFGPRSKGWVCKK-NH₂ 9 146 169 Isovalericacid-DTAFPCIIFGPRSKGWVCK-NH₂ 24 147 170 Isovalericacid-DTKFPCIIFGPRSKGWVCK-NH₂ 20 148 171 Isovalericacid-DTHFPC₁IIFVC₂HRPKGC₂YRRVC₁R- 2.2 NH₂ 149 172 Isovalericacid-DTHFPCI-K(PEG8)-FGPRSKGWVCK- 9 NH₂ 150 173 Isovalericacid-DTHFPCIKF-K(PEG8)-PRSKGWVCK- 7 NH₂ 151 174 Isovalericacid-DTHFPCIKFGP-K(PEG8)-SKGWVCK- 13 NH₂ 152 175 Isovalericacid-DTHFPCIKFGPRS-K(PEG8)-GWVCK- 16 NH₂ 153 176 Isovalericacid-DTHFPCIKFGPRSKGWVC-K(PEG8)- 18 NH₂ 154 177 Isovalericacid-DTHFPCIKFGPRSKGWTCK-NH₂ 18 155 178 Isovalericacid-DTHFPCIEFGPRSKGWTCK-NH₂ 38 156 179 Isovalericacid-DTHFPICIFGPRS-K(Betaine)-GWVC- Not Tested NH₂ 157 180 Isovalericacid-DTHFPCIKFGPRS-K(Betaine)-GWVCK- 18 NH₂ 158 181 Isovalericacid-DTHFPCI-K(Betaine)-FGPRSKGWVCK- 16 NH₂ 159 182 Isovalericacid-DTHFPCIKFGPRSKGWVC-K(Betaine)- 17 NH₂ 160 183Ac-DTHFPCIKFGPRSKGWVCK-NH₂ 464 161 184 Isovalericacid-PEG3-DTHFPCIKFGPRSKGWVCK-NH₂ 666 162 185 Isobutyricacid-DTHFPCIKFGPRSKGWVCK-NH₂ 41 163 186 Valericacid-DTHFPCIKFGPRSKGWVCK-NH₂ 64 164 187 Hy-VDTHFPCIKFGPRSKGWVCK-NH₂ 146165 188 Hy-LDTHFPCIKFGPRSKGWVCK-NH₂ 107 166 189 Hexanoicacid-DTHFPCIKFGPRSKGWVCK-NH₂ 36 167 190 5-Methylpentanoicacid-DTHFPCIKFGPRSKGWVCK- 99 NH₂ 168 191 Cyclohexanoicacid-DTHFPCIKFGPRSKGWVCK-NH₂ 30 169 192 Heptanoicacid-DTHFPCIKFGPRSKGWVCK-NH₂ 91 170 193 Octanoicacid-DTHFPCIKFGPRSKGWVCK-NH₂ 183 171 194 Isovalericacid-DTHFPCIIFGPRSKGWKCK-NH₂ 48 172 195 Isovalericacid-DTHFPCIIFGPRSKGWECK-NH₂ 15 173 196 Isovalericacid-DTHFPCRRFGPRSKGWVCK-NH₂ Not Tested 176 199 Isovalericacid-DTHFPICIFGPRS-K(PEG8)-GWVC-NH₂ 6 177 200 Isovalericacid-DTHFPICIFGPRS-K(PEG4)-GWVC-NH₂ 6 178 201 Isovalericacid-DTHFPCIIFGPRSRGWVC-K(PEG8)- 3 NH₂ 179 202 Isovalericacid-DTHFPCIIFGPRSRGWVC-K(PEG4)- 4 NH₂ 180 203 Isovalericacid-DTHFPCIIFGPRSRGWVC-K(PEG2)- 9 NH₂ 181 204 Isovalericacid-DTHFPCIKFEPRSKGWVCK-NH2 15 182 205 Isovalericacid-DTHFPCIKFEPRSKGWTCK-NH₂ 13 183 206 Isovalericacid-DTHFPCIKFEPRSKGWCK-NH₂ 17 184 207 Isovalericacid-DTHFPCIKFEPRSKGCK-NH₂ 23 185 208 Isovalericacid-DTHFPCIFEPRSKGCK-NH₂ 54 186 209 Isovalericacid-DTHFPCIFEPRSKGWCK-NH₂ 12 187 210 Isovalericacid-DTHFPCIKFGPRSKCK-NH₂ 21 188 211 Isovaleric acid-DTHFPCIKFGPRSCK-NH₂30 189 212 Isovaleric acid-DTHFPCIKFGPRCK-NH₂ 36 190 213 Isovalericacid-DTHFPCIKFGPCK-NH₂ 55 191 214 Isovaleric acid-DTHFPCIKFGCK-NH₂ 97192 215 Isovaleric acid-DTHFPCIKFCK-NH₂ 48 193 216 Isovalericacid-DTHFPCIKFC-NH₂ 80 194 217 Isovalericacid-DTHFPCI-K(Palm)-FGPRSKGWVCK- 4 NH₂ 195 218 Isovalericacid-DTHFPCIKF-K(Palm)-PRSKGWVCK- 9 NH₂ 196 219 Isovalericacid-DTHFPCIKFGP-K(Palm)-SKGWVCK- 2 NH₂ 197 220 Isovalericacid-DTHFPCIKFGPRS-K(Palm)-GWVCK- 1 NH₂ 198 221 Isovalericacid-DTHFPCIKFGPRSKGWVC-K(Palm)- 7 NH₂ 199 222 Isovalericacid-DTHFPCI-K(PEG3-Palm)- 7 FGPRSKGWVCK-NH₂ 200 223 Isovalericacid-DTHFPCIKF-K(PEG3-Palm)- 6 PRSKGWVCK-NH₂ 201 224 Isovalericacid-DTHFPCIKFGP-K(PEG3-Palm)- 4 SKGWVCK-NH₂ 202 225 Isovalericacid-DTHFPCIKFGPRS-K(PEG3-Palm)- 3 GWVCK-NH₂ 203 226 Isovalericacid-DTHFPCIKFGPRSKGWVC-K(PEG3- 4 Palm)-NH₂ 204 227Hy-DTHFPCI-K(IVA)-FGPRSKGWVCK-NH₂ >300 nM   205 228Hy-DTHFPCIKF-K(IVA)-PRSKGWVCK-NH₂ >300 nM   206 229Hy-DTHFPCIKFGP-K(IVA)-SKGWVCK-NH₂ 624 207 230Hy-DTHFPCIKFGPRS-K(IVA)-GWVCK-NH₂ 318 208 231Hy-DTHFPCIKFGPRSKGWVC-K(IVA)-NH₂ 109 209 232Hy-DTHFPCI-K(PEG3-IVA)-FGPRSKGWVCK-NH₂ 342 210 233Hy-DTHFPCIKF-K(PEG3-IVA)-PRSKGWVCK-NH₂ 457 211 234Hy-DTHFPCIKFGP-K(PEG3-IVA)-SKGWVCK-NH₂ >300 nM   212 235Hy-DTHFPCIKFGPRS-K(PEG3-IVA)-GWVCK-NH₂ >300 nM   213 236Hy-DTHFPCIKFGPRSKGWVC-K(PEG3-IVA)-NH₂ 233 214 237 Isovalericacid-DTHFPCIKFEPRSKKWVCK-NH₂ 15 215 238 Hy-DTHFPCIKFGPRSKGWVCK-NH₂ >1 μM216 239 Palm-DTHFPCIKFGPRSKGWVCK-NH₂ >1 μM 217 240Palm-PEG3-DTHFPCIKFGPRSKGWVCK-NH₂ >1 μM 218 241 Isovalericacid-DTHFPCI-K(isoglu-Palm)-FEPRSKGCK- 10 NH₂ 219 242 Isovalericacid-DTHFPCIKF-K(isoglu-Palm)-PRSKGCK- 9 NH₂ 220 243 Isovalericacid-DTHFPCIKFEP-K(isoglu-Palm)-SKGCK- 5 NH₂ 221 244 Isovalericacid-DTHFPCIKFEPRS-K(isoglu-Palm)-GCK- 4 NH₂ 222 245 Isovalericacid-DTHFPCIKFEPRSK-K(isoglu-Palm)-CK- 4 NH₂ 223 246 Isovalericacid-DTHFPCIKFEPRSKGC-K(isoglu-Palm)- 5 NH₂ 224 247 Isovalericacid-DTHFPCIKFEPRSKGCK-K(isoglu- 4 Palm)-NH₂ 225 248 Isovalericacid-DTHFPCI-K(dapa-Palm)-FEPRSKGCK- 17 NH₂ 226 249 Isovalericacid-DTHFPCIKF-K(dapa-Palm)-PRSKGCK- 14 NH₂ 227 250 Isovalericacid-DTHFPCIKFEP-K(dapa-Palm)-SKGCK- 10 NH₂ 228 251 Isovalericacid-DTHFPCIKFEPRS-K(dapa-Palm)-GCK- 7 NH₂ 229 252 Isovalericacid-DTHFPCIKFEPRSK-K(dapa-Palm)-CK- 13 NH₂ 230 253 Isovalericacid-DTHFPCIKFEPRSKGC-K(dapa-Palm)-K- 10 NH₂ 231 254 Isovalericacid-DTHFPCIKFEPRSKGCK-K(dapa-Palm)- 11 NH2 232 255 Isovalericacid-DTHFPCIKFGPRSKGWVCK-NH₂ Not Tested 233 256 Isovalericacid-AAHFPCIKFGPRSKGWVCK-NH₂ 320 234 257 Isovalericacid-ATHFPCIKFGPRSKGWVCK-NH₂ 60 235 258 Isovalericacid-DAHFPCIKFGPRSKGWVCK-NH₂ 203 236 259 Isovalericacid-DTHAPCIKFGPRSKGWVCK-NH₂ >500 nM   237 260 Isovalericacid-DTHFPCIKAGPRSKGWVCK-NH₂ 50 238 261 Isovalericacid-DTHFPCIKFEPRSKGWVCK-OH 47 239 262 Isovalericacid-DTHFPCIKFEPRSKGWECK-OH 101 240 263 Isovalericacid-DTHFPCIIFEPRSKGWEC-OH 139 241 264 Isovalericacid-DTHFPCIKFK(isoGlu-Palm)- 6 PRSKGWECK-NH₂ 242 265 Isovalericacid-DTHFPCIKFEPK(isoGlu-Palm)- 8 SKGWECK-NH₂ 243 266 Isovalericacid-DTHAPCIKFEPRSKGWECK-NH₂ Inactive 244 267Ida-THFPCIKFEPRSK-K(isoGlu-Palm)CK-NH₂ 25 245 268 Isovalericacid-DTHFPCI-K(isoGlu-Palm)- 131 FEPRSKGWEC-OH 246 2694,4-5,5-6,6,6-Heptafluorohexanoic acid- 480 DTHFPCIKFGPRSKGWVCK-NH₂ 247270 Isovaleric acid-DTHFPCIKF-K(mysteric acid)- 7 PRSKGWVC-NH₂ 248 271Isovaleric acid-DTHFPCIKF-K(lauric acid)- 10 PRSKGWVC-NH₂ 249 272Isovaleric acid-DTHFPCIKF-K(decanoic acid)- 22 PRSKGWVC-NH₂ 250 273Isovaleric acid-DTHFPCIKF-K(octanoic acid)- 30 PRSKGWVC-NH₂ 251 274Isovaleric acid-DTHFPCIKF-K(hexanoic acid)- 21 PRSKGWVC-NH₂ 252 275Isovaleric acid-DTHFPCIKF-K(butyric acid)- 37 PRSKGWVC-NH₂ 253 276Isovaleric acid-DTHFPCIKF-K(Ac)-PRSKGWVC-NH₂ 29 254 277Ida-THFPCIKFEPRSKGWVC-K(mysteric acid)-NH₂ 20 255 278[Ida]-THFPCIKFEPRSKGWVC-K(lauric acid)-NH₂ 52 256 279[Ida]-THFPCIKFEPRSKGWVC-K(decanoic acid)-NH₂ 116 257 280[Ida]-THFPCIKFEPRSKGWVC-K(octanoic acid)-NH₂ 129 258 281[Ida]-THFPCIKFEPRSKGWVC-K(hexanoic acid)-NH₂ 191 259 282[Ida]-THFPCIKFEPRSKGWVC-K(butyric acid)-NH₂ 355 260 283[Ida]-THFPCIKFEPRSKGWVC-K(Ac)-NH₂ 502 261 284 Isovalericacid-HFPCIKFEPRSKGWVC-K(octanoic >300 nM   acid)-NH₂ 262 285 Isovalericacid-HFPCIKFEPRSKGWVC-K(lauric 77 acid)-NH₂ 263 286 Isovalericacid-DTHFPCIKFEPHSKGCK-NH2 62 264 287 Isovalericacid-DTHFPCIHFEPHSKGC-NH₂ 118 265 288 Isovalericacid-DTHFPCIKFEPHS-K(Albu)-GCK-NH₂ 6 266 289 Isovalericacid-DTHFPCIKFEPREKEC-NH₂ 183 267 290 Isovalericacid-DTAFPCIKFEPRSKEC-NH₂ >1 μM 268 291 Isovaleric acid-DTHFPCIKFECK-NH₂107 269 292 Hy-DTHFPIAIFAAGICI-NH₂ Inactive 270 293Hy-DTHFPIAIFAAICI-NH₂ Inactive 271 294 Hy-DTHFPIAIFAICI-NH₂ Inactive 272295 Hy-DTHFPIAIFICI-NH₂ Inactive 273 296 Hy-DTHFPIAIICI-NH₂ Inactive 274297 Hy-DTHFPIAICI-NH₂ Inactive 275 298 Hy-DTHFPIICI-NH₂ Inactive 276 299Hy-DTHICIAIF-NH₂ Inactive 277 300 Hy-DTHCPIAIF-NH₂ Inactive 278 301Hy-DTHFPCIIA-NH₂ >1 μM 279 302 Hy-DTHFPCAIF-NH₂ >1 μM 280 303Hy-DTHFACIIF-NH₂ >1 μM 281 304 Hy-DTHF-(D)--Ala-CIIF-NH₂ Inactive 282305 Hy-DTHAPCIIF-NH₂ Inactive 283 306 Hy-DTAFPCIIF-NH₂ 739 nM  284 307Hy-ATHFPCIIF-NH2 >1 μM 285 308 [Ida]-THF-[bh-Pro]-CIIF-NH₂ >1 μM 287 310Hy-DTHFPCIEF-NH₂ >1 μM 288 311 Isovaleric acid-DTHFPCIIF-NH₂ 16 nM 289312 Isovaleric acid-DTHFPAIIF-NH2 Inactive 290 313 Isovalericacid-DTHFPSIIF-NH2 Inactive 291 314 Isovaleric acid-DTHFPCIKF-NH₂  7 nM293 316 Hy-DTHFPCIF-NH₂ 52% at 1 μM 297 320 Hy-DTHFPCIKFF-NH₂ 64% at 1μM 298 321 Hy-YTHFPCIIF-NH₂ Not Tested 299 322 Hy-LTHFPCIIF-NH₂ 64% at 1μM 300 323 Hy-ETHFPCIIF-NH₂ 77% at 1 μM 301 324 Hy-DRHFPCIIF-NH₂ NotTested 302 325 Hy-DTKFPCIIF-NH₂ 60% at 1 μM 303 326 Hy-DTHFECIIF-NH₂ NotTested 304 327 Hy-DTHFPCIIK-NH₂ 55% at 1 μM 305 328 Hy-DTHFPCIIR-NH₂ 62%at 1 μM 306 329 Hy-DTHFPCIEF-NH₂ Not Tested 307 330 Hy-DTHFPCIVF-NH₂ 75%at 1 μM 308 331 Hy-DTHFPCILF-NH₂ 89% at 1 μM 309 332 Hy-DTHFPCILK-NH₂55% at 1 μM 310 333 Hy-DTHFPCIEK-NH₂ 0% at 1 μM 355 369 Isovalericacid-DTHFPCIKFEPRSKECK-NH₂ 48 356 370 Isovalericacid-DTHFPCIKFEPHSKECK-NH₂ 181 357 371 Isovalericacid-DTHFPCIKKEPHSKECK-NH₂ >1 μM 358 372 Isovalericacid-DTHFPCIKF-K(isoglu-Palm)-PHSKECK-NH₂ 6 359 373 Isovalericacid-DTHFPCIKFEPRECK-NH₂ 64 360 374 Isovaleric acid-DTHFPCIKFEPHECK-NH₂138 361 375 Isovaleric acid-DTHFPCIKFEPRCK-NH₂ 29 Inactive = Not activeat 30 μM and/or lowest dose. For Table 7, parentheticals, e.g., (_),represent side chain conjugations and brackets, e.g., [_], representunnatural amino acid substitutions. For certain compounds comprising anN-terminal PEG11 moiety (e.g., compounds 89, 108, and 109), thefollowing was used in their synthesis:

Fmoc-amino PEG Propionic Acid

Example 6 Alanine Scan of Compound 18

To further understand Hepcidin's structure activity relationship, analanine scan was performed on Compound 18, which is a Hepcidin analogueof the present invention that comprises a cysteine in the 7 position.Peptides were synthesized as described in Example 1 and tested foractivity as described in Example 2; results are shown in Table 8 herein.

TABLE 8 Alanine scan of Compound 18 SEQ Compound ID EC50 Number No.Sequence (nM) (n > 3) 18 45 DTHFPICIFGPRSKGWVCM-NH₂ 125 47 74DTHFPICIFGPRSKGW A CM-NH₂ 313 66 89 DTHFPICIFGPRSKG A VCM-NH₂ 520 31 58DTHFPICIFGPRSK A WVCM-NH₂ 175 37 64 DTHFPICIFGPRS A GWVCM-NH₂ 239 16 43DTHFPICIFGPR A KGWVCM-NH₂ 88 34 61 DTHFPICIFGP A SKGWVCM-NH₂ 206 354 334DTHFPICIFG A RSKGWVCM-NH₂ 153 22 49 DTHFPICIF A PRSKGWVCM-NH₂ 9430 67 90DTHFPICI A GPRSKGWVCM-NH₂ 2466 68 91 DTHFPIC A FGPRSKGWVCM-NH₂ >10 μM 6992 DTHFPI A IFGPRSKGWV A M-NH₂ Inactive 29 56 DTHFP A CIFGPRSKGWVCM-NH₂157 26 53 DTHF A ICIFGPRSKGWVCM-NH₂ 147 38 65 DTH A PICIFGPRSKGWVCM-NH₂254 60 87 DT A FPICIFGPRSKGWVCM-NH₂ 498 43 70 D A HFPICIFGPRSKGWVCM-NH₂265 33 60 ATHFPICIFGPRSKGWVCM-NH₂ 184 Inactive = Not active at 30 μMand/or lowest dose

As was the case with the alanine scan of compound 1 (cysteine inposition 6) this scan identified residues within compound 18 (cysteinein position 7) that are important for activity, as well as severalresidues that appear to be less important for activity and thus maymodified without ablating activity.

Example 7 Plasma Stability

Serum stability experiments were undertaken to complement the in vivoresults and assist in the design of potent, stable Ferroportin agonists.In order to predict the stability in humans, ex vivo stability studieswere initially performed in human serum.

Key peptides (10 μM) were incubated with pre-warmed human serum (Sigma)at 37 degrees C. Samples were taken at various time points up to 24hours. The samples were separated from serum proteins and analysed forthe presence of the peptide of interest using LC-MS. The amount ofintact peptide in each sample was calculated using the analyte peak areain relation to the zero time point. Table 9 shows the results of thisstudy.

TABLE 9 Stability of key compounds in human serum Compound No. t½ (h)Hepcidin 2.76 Mini Hepcidin 1-9 0.10 1 0.18 18 2.32 46 2.10 2 1.99 47~40 8 0.51 3 0.51

Example 8 Reduction of Free Plasma Iron in Rats

To investigate whether the hepcidin mimetic Compound No. 2 was effectivein decreasing free Fe²⁺ in serum, Retro Inverse mini Hepcidin was usedas a reference peptide. Although RI mini-Hep has a very low potency invitro it is highly active in vivo as reported by Presza et al. J ClinInvest. 2011.

At Day 1, the animals were monitored for free Fe²⁺ in serum. In order toreach a homogenous serum level, Fe²⁺ was analyzed and a homogenouscohort of 7 or 8 animals randomized to each treatment group. At Day 2,an acute experiment where the animals were subjected to i.p. dosing oftest compound and subsequent tail vein blood samples. Prior to dosing,the animals were put under a heating lamp for 3-5 minutes. Blood sampleswere drawn from the tail vein from all animals in order to determineserum iron levels prior to vehicle or compound dosing. Animals weredosed i.p. with 1 ml of test substance in vehicle or just vehicle andblood samples of 250 μl was drawn from each animal at t=0, 60, 120, 240,360 min and 24 hours in the study of the reference compound. The doseresponse study performed with Retro Inverse (RI) mini-Hepcidin(Reference compound), and the efficacy study performed with Compound No.2 were performed as two separate experiments.

Analysis of Fe²⁺ from Day 0 and 1 was done at a later time point notlater than 10 days after. The chemicals and equipment used in thisexample are shown in Table 10.

TABLE 10 Chemicals and equipment used in this example Peptide PeptideCmpd. SEQ ID MW Content Content Purity Drug Name No. No. (g/mol)Calculated % Determined % % Solvent Isovaleric 2 29 2144.52 86.2 86.2 90Na- acid- Acetate DTHFPICIF buffer GPRSKGW VC-NH₂ RI- 337 1091.3 82.782.7 94.2 Strong Hepcidin1-9 PBS

Initially, all peptides were solubilized in acidic H₂O in pH=2.5 and toa concentration of 3 mg/ml API. Compounds were thereafter eitherdissolved in Na-Acetate buffer (50 mM Acetic Acid, 125 mM NaCl, pH 5.0)or strong PBS, (25 mM sodium phosphate, 125 mM NaCl, pH 7.4).

Male Sprague-Dawley rats weighing 200-250 g were used in the study. Theywere housed in groups for n=2 in a light-, temperature- andhumidity-controlled room (12-hour light: 12-hour dark cycle, lightson/off at 0600/1800 hour; 23 degrees Celcius; 50% relative humidity).Humane endpoints were applied, according to OECD's ‘Guidelines forEndpoints in Animal Study Proposals.” The animals were monitored daily.In case of significantly affected condition (based on signs such asweight loss>30% (obese animals); abnormal posture; rough hair coat;exudate around eyes and/or nose; skin lesions; abnormal breathing;difficulty with ambulation; abnormal food or water intake; or selfmutilation), or other conditions causing significant pain or distress,the animals were euthanized immediately.

Iron content in plasma/serum is measured for iron content using acolorimetric assay on the Cobas c 111 according to instructions from themanufacturer of the assay (assay: IRON2: ACN 661).

The data obtained from the cobas Iron2 analysis are presented as meanvalues +/−SEM.

As shown in FIGS. 2 and 3, IP dosing of compound 2 resulted in adecrease in serum iron level that was comparable to that observed afterinjection of the positive control Retro Inverse mini Hepcidin(RI-Mini-Hepcidin). The decrease induced by RI-Mini-Hepcidin andcompound 2 was in neither case significant, which was probably due to alarge intergroup variance in the measurements.

Example 9 In Vivo Validation of Selected Peptides

Selected peptides of the present invention were tested for in vivoactivity, as described in Example 8, with the following changes. Insteadof rats, mice (C57-BL6) were tested. Peptides or vehicle controls wereadministered to the mice (n=8/group) with the compounds of the presentinvention dosed at 3000 nmol/kg, and a hepcidin control administered viasubcutaneous injection at 1000 nmol/kg. The primary goal of thisexperiment was to validate, in a mouse model, the activity of severalpeptides that were shown to be active in rat. Serum iron levels wereassessed as in Example 8 two hours after peptide or vehicleadministration. As shown in FIG. 4, at these doses, a significantreduction in serum iron was observed in compound-treated animals ascompared to the vehicle control. Furthermore, the max-dose responses ofthe compounds of the invention were very similar to the max-doseresponse achieved with Hepcidin.

A similar experiment was performed with lower doses to assess the doseresponse of these compounds for inducing serum iron reduction. Methodswere as described above in this Example, except for the followingparameters: n=4 mice/group, however n=8 for the vehicle, as two groupswere pooled. Mice were administered test compounds at two separatedosages (300 nmol/kg or 1000 nmol/kg), via subcutaneous injection. Serumiron levels were assessed as in Example 8 two hours after peptide orvehicle injection. As shown in FIG. 5, these peptides induced similariron reductions as did native hepcidin in vivo. Moreover, it was clearthat several of the compounds were able to induce maximum effects atdosages as low as 300 nmol/kg.

Other peptides were tested similarly, either in rats as described inExample 8, or in mice as described above in the present Example, and theresults of these tests are presented in Table 11, herein, in the columnhaving the heading “in vivo activity.” In this table, dosing isindicated in the sub-headings listed in the first row of the “in vivoactivity” column; in vivo activity data is reported as a “yes” or “no”determination, with yes indicating that in vivo activity for serum ironreduction was observed, and with “no” indicating that no such activitywas observed. The route of peptide administration was via subcutaneousinjection, unless otherwise indicated as having been via intraperitonealinjection (this is noted on the table by “i.p.” in parentheses followingthe “yes” or “no” determination).

The peptides were also tested for other pharmacokinetic/pharmacodynamic(PK/PD) parameters using methods commonly know by the skilled artisan.The results of these tests are also indicated on Table 11. Theseparameters included determinations regarding stability (hours stable inplasma from the indicated human or rat subject), half-life in mice, andin vitro activity (EC₅₀), tested as described in Example 2. One exampleof such a study is presented in FIG. 6, wherein the PK/PD properties oftwo compounds of the present invention (#153 and #181) were comparedwith hepcidin to determine their PK/PD effects in C57BL6 mice. Each ofthese compounds produced a rapid decrease in serum iron, which wastransient in the case of Cmpd #181, and sustained in the case of Cmpd#153.

These data, in addition to the data presented herein in Table 11,demonstrated the activity and beneficial PK/PD properties of thepeptides of the present invention, a plurality of which show similar orimproved PK/PD profiles as compared to hepcidin.

TABLE 11 Peptide activities in vivo Mouse In Vivo PK Activity In VivoCmpd Stability T_(1/2) EC50 Activity (s.c.) No Sequence Rat Human (min)(nM) 300 nmol/kg 1000 nmol/kg Hepcidin Hy- Var 2.76 34 Yes YesDTHFPICIFCCGCCHRS KCGMCCKT-OH SEQ ID NO: 335 2 Isovaleric acid- 0.151.99 17.4 5 Yes Yes DTHFPICIFGPRSKGW VC-NH₂ (SEQ ID NO: 29) 3 Isovalericacid- 0.08 0.43 15 No (i.p.) No (i.p.) DTHFPCIIFGPRSRGWV CK-NH₂ (SEQ IDNO: 30) 105 Isovaleric acid- 0.68 2.22 36.9 10 Yes Yes DTHFPCIIFEPRSKGWVCK-NH₂ (SEQ ID NO: 128) 9 Isovaleric acid- 0.14 0.57 22.5 32 Yes YesDTHFPCIKFGPRSKGW VCK-NH₂ (SEQ ID NO: 36) 10 Isovaleric acid- 0.12 35 —Minor DTHFPCIQFGPRSKGW VCK-NH₂ (SEQ ID NO: 37) 15 Isovaleric acid- 0.1579 — Minor DTHFPICIEFGPRSKGW VCK-NH₂ (SEQ ID NO: 42) 115 Isovalericacid- 21 — No DTHFPCIIFGPRSKGCK- NH₂ (SEQ ID NO: 138) 150 Isovalericacid- 0.42 1.35 31.6 7 Yes DTHFPCIKFK(PEG8)PR SKGWVCK-NH₂ (SEQ ID NO:173) 153 Isovaleric acid- 0.41 3.36 18 Yes Yes DTHFPCIKFGPRSKGWVCK(PEG8)-NH₂ (SEQ ID NO: 176) 176 Isovaleric acid- 1.62 15 6 YesDTHFPICIFGPRSK(PEG 8)GWVC-NH₂ (SEQ ID NO: 199) 184 Isovaleric acid- 2.128.16 36.9 16 Yes Yes DTHFPCIKFEPRSKGC K-NH₂ (SEQ ID NO: 207) 181Isovaleric acid- 15 Yes DTHFPCIKFEPRSKGW VCK-NH₂ (SEQ ID NO: 204) Unlessotherwise stated all compounds were injected s.c. Note Compound 2 wasinjected I.P.

Example 10 In Vitro Activity of Selected Peptide Dimers

Selected peptide dimers of the present invention were tested for invitro activity, as described in Example 2.

The EC₅₀ and % activity at 1 μM were determined for the peptide monomersand peptide dimers shown in Table 12. These peptide dimers weredimerized via a single disulphide linkage between a cysteine residuepresent in each peptide monomer. The results of these experiments areshown in Table 12.

TABLE 12 In vitro activity of peptides dimerized through a singledisulphide linkage between cysteine residues % EC₅₀ Activity EC₅₀ % (nM)At 1 (nM) Activity Cmpd # Sequence (n = 3) uM) Cmpd # Sequence (n = 3)At 1 uM 1 Hy-DTHFPCIIF-NH₂ 133 92 311 (Hy-DTHFPCIIF-NH₂)₂ 35 96 (SEQ IDNO: 28) (SEQ ID NO: 338) 293 Hy-DTHFPCIF-NH₂ >1 μM 52 312(Hy-DTHFPCI_F-NH₂)₂ >300 nM 51 (SEQ ID NO: 316) (SEQ ID NO: 339) 297Hy-DTHFPCIKFF- >300 nM 64 314 (Hy-DTHFPCIKFF- 130 100 NH₂ (SEQ ID NO:320) NH₂)₂ (SEQ ID NO: 341) 299 Hy-LTHFPCIIF-NH₂ >300 nM 64 315(Hy-LTHFPCIIF-NH₂)₂ 35 97 (SEQ ID NO: 322) (SEQ ID NO: 342) 300Hy-ETHFPCIIF-NH₂ >300 nM 77 316 (Hy-ETHFPCIIF-NH₂)₂ 63 100 (SEQ ID NO:323) (SEQ ID NO: 343) 302 Hy-DTKFPCIIF-NH2 >1 μM 60 317(Hy-DTKFPCIIF-NH₂)₂ 137 87 (SEQ ID NO: 325) (SEQ ID NO: 344) 304Hy-DTHFPCIIK-NH₂ >1 μM 55 318 (Hy-DTHFPCIIK-NH₂)₂ >300 nM 49 (SEQ ID NO:327) (SEQ ID NO: 345) 305 Hy-DTHFPCIIR-NH₂ >1 μM 62 319(Hy-DTHFPCIIR-NH₂)₂ 268 79 (SEQ ID NO: 328) (SEQ ID NO: 346) 307Hy-DTHFPCIVF-NH₂ >300 nM 75 320 (Hy-DTHFPCIVF-NH₂)₂ 50 93 (SEQ ID NO:330) (SEQ ID NO: 347) 308 Hy-DTHFPCILF-NH₂ >300 nM 89 321(Hy-DTHFPCILF-NH₂)₂ 83 94 (SEQ ID NO: 331) (SEQ ID NO: 348) 309Hy-DTHFPCILK-NH₂ >300 nM 55 322 (Hy-DTHFPCILK-NH₂)₂ >300 nM 47 (SEQ IDNO: 332) (SEQ ID NO: 349) 310 Hy-DTHFPCIEK-NH₂ >1 μM 0 323(Hy-DTHFPCIEK-NH₂)₂ >1 μM 0 (SEQ ID NO: 333) (SEQ ID NO: 350) 288Isovaleric acid- 16 100 325 (Isovaleric acid- 4 100 DTHFPCIIF-NH₂DTHFPCIIF-NH₂)₂ (SEQ ID NO: 311) (SEQ ID NO: 351) 291 Isovaleric acid- 7100 326 (Isovaleric acid- 3 100 DTHFPCIKF-NH₂ DTHFPCIKF-NH₂)₂ (SEQ IDNO: 314) (SEQ ID NO: 352)

EC₅₀ values were also determined for the peptide dimers having thesequences shown in Table 10. The activity of peptide dimers dimerizedonly through a disulphide linkage between the two peptide monomers wascompared to the activity of peptide dimers of the same monomersdimerized through both the disulphide linkage and also a DIG linkingmoiety. In addition, the activity of peptide dimers dimerized through aDIG linking moiety coupled to the N-terminus of the monomers, theC-terminus of the monomers, or different internal lysine residues wasexamined. The results of these experiments are provided in Table 13.

TABLE 13 Dimer Position explored (DIG as the representative linkerexplored) EC₅₀ Cmpd (nM) No. Sequence (n > 3) 327 (DTHFPCIKF-NH₂)₂ 193(SEQ ID NO: 353)

328 DIG-(DTHFPCIKF-NH₂)₂ DIG through N-terminus >1000 (SEQ ID NO: 354)

329 (Isovaleric acid-DTKFPCIRF-NH₂)₂ 9 (SEQ ID NO: 355)

340 (Isovaleric acid-DTKFPCIRF-NH₂)₂ DIG through K3 212 (SEQ ID NO: 356)

326 (Isovaleric acid-DTHFPCIKF-NH₂)₂ 3 (SEQ ID NO: 357)

342 (Isovaleric acid-DTHFPCIKF-NH₂)₂ DIG through K8 10 (SEQ ID NO: 358)

343 (Isovaleric acid-DTHFPCIRK-NH₂)₂ 11 (SEQ ID NO: 359)

344 (Isovaleric acid-DTHFPCIRK-NH₂)₂ DIG through K9 45 (SEQ ID NO: 360)

345 (Isovaleric acid-DTHFPCIKFK-NH₂)₂ 8 (SEQ ID NO: 361)

346 (Isovaleric acid-DTHFPCIKFK-NH₂)₂ DIG through K10 15 (SEQ ID NO:362)

EC₅₀ values were determined for peptide dimers comprising differentlinking moieties, and as compared to linkage via a disulphide bridgebetween the two peptide monomers,

EC₅₀ values were determined for peptide dimers comprising differentlinking moieties, and as compared to linkage via a disulphide bridgebetween the two peptide monomers, including the peptide dimers shown inTable 14. Where a particular linking moiety is not indicated, thepeptide dimer was dimerized via a disulphide bridge between cysteineresidues present in each of the peptide monomers of the peptide dimer.The results of this experiment are shown in Table 14, and various linkertypes are shown as schematics in FIG. 7.

TABLE 14 Dimerization using various linkers at different positions Logdilutions Cmpd. No. Sequence EC₅₀ (nM) (n > 3) 327 (Hy-DTHFPCIKF-NH₂)₂(SEQ ID NO: 353) 193 348 (Hy-DTHFPCIKF-NH₂)₂-[IDA-(β-Ala)] (SEQ ID 18NO: 363) 326 (Isovaleric acid-DTHFPCIKF-NH₂)₂ (SEQ ID 6 NO: 357) 349(Isovaleric acid-DTHFPCIKF-NH₂)₂-[IDA-(β-Ala)- 5 Palm] (SEQ ID NO: 364)345 (Isovaleric acid-DTHFPCIKFK-NH₂)₂ (SEQ ID 8 NO: 361) 346 (Isovalericacid-DTHFPCIKFK-NH₂)₂-[DIG] 15 DIG through K10 (SEQ ID NO: 362) 327(Hy-DTHFPCIKF-NH₂)₂ (SEQ ID NO: 353) 193 351 [PEG25]-(DTHFPCIKF-NH₂)₂(SEQ ID NO: 366) >1000In Table 14, brackets indicate linker and any linker conjugates (ifpresent), e.g., [linker].

EC₅₀ values were determined for peptide dimers dimerized via a glycollinker attached to the EN of lysine residues within the peptide chains,as compared to the peptide monomers. As shown in Table 15, the peptidedimers had lower EC_(50S) than their corresponding peptide monomers. Inthis case, the disulphide bond exists intramolecularly within eachpeptide (e.g., cmpd #2 and cmpd #3) moiety before dimerization throughusing DIG through acylation of the Nε of lysine.

TABLE 15 Dimerization through a glycol linker attached to the ε_(N) oflysine within the peptide chain Log dilutions Cmpd EC₅₀ (nM) No.Sequence (n > 3) 3 Isovaleric acid-DTHFPCIIFGPRSRGWVCK- 15 NH₂ (SEQ IDNO: 30) 352 (Isovaleric acid- 5 DTHFPCIIFGPRSRGWVCK-NH₂)₂-[DIG] (SEQ IDNO: 367) 2 Isovaleric acid-DTHFPICIFGPRSKGWVC- 4.1 NH₂ (SEQ ID NO: 29)353 (Isovaleric acid-DTHFPICIFGPRSKGWVC- 2.2 NH₂)₂-[DIG] (SEQ ID NO:368)

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in the Application Data Sheet, are incorporated herein byreference, in their entirety.

Having thus described exemplary embodiments of the present invention, itshould be noted by those skilled in the art that the within disclosuresare exemplary only and that various other alternatives, adaptations, andmodifications may be made within the scope of the present invention.Accordingly, the present invention is not limited to the specificembodiments as illustrated herein, but is only limited by the followingclaims.

1-56. (canceled)
 57. A peptide having the following structural formulaI′R1′-X′-Y′-R2′  (I′) (SEQ ID NO:21) or a pharmaceutically acceptable saltthereof, wherein R1′ is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C1-C20alkanoyl or pGlu; R2′ is —NH₂ or —OH; X′ is a peptide sequence havingthe formula Ia′X1-X2-X3-X4-X5-X6-X7-X8-X9-X10   (Ia′) (SEQ ID NO:13) wherein X1 is Asp,Ala, Ida, pGlu, bhAsp, Leu, D-Asp or absent; X2 is Thr, Ala, or D-Thr;X3 is His, Lys, D-His or Lys; X4 is Phe, Ala, Dpa or D-Phe; X5 is Pro,Gly, Arg, Lys, Ala, D-Pro or bhPro; X6 is Ile, Cys, Arg, Lys, D-Ile orD-Cys; X7 is Cys, Ile, Leu, Val, Phe, D-Ile or D-Cys; X8 is Ile, Arg,Phe, Gln, Lys, Glu, Val, Leu or D-Ile; X9 is Phe or bhPhe; and X10 isLys, Phe or absent; wherein if Y′ is absent, X7 is Ile; and Y′ is apeptide sequence having the formula IIa′Y1-Y2-Y3-Y4-Y5-Y6-Y7-Y8-Y9-Y10-Y11-Y12-Y13-Y14-Y15   (IIa′) (SEQ IDNO:16) wherein Y1 is Gly, Cys, Ala, Phe, Pro, Glu, Lys, D-Pro, Val, Seror absent; Y2 is Pro, Ala, Cys, Gly or absent; Y3 is Arg, Lys, Pro, Gly,His, Ala, Trp or absent; Y4 is Ser, Arg, Gly, Trp, Ala, His, Tyr orabsent; Y5 is Lys, Met, Arg, Ala or absent; Y6 is Gly, Ser, Lys, Ile,Ala, Pro, Val or absent; Y7 is Trp, Lys, Gly, Ala, Ile, Val or absent;Y8 is Val, Thr, Gly, Cys, Met, Tyr, Ala, Glu, Lys, Asp, Arg or absent;Y9 is Cys, Tyr or absent; Y10 is Met, Lys, Arg, Tyr or absent; Y11 isArg, Met, Cys, Lys or absent; Y12 is Arg, Lys, Ala or absent; Y13 isArg, Cys, Lys, Val or absent; Y14 is Arg, Lys, Pro, Cys, Thr or absent;and Y15 is Thr, Arg or absent; wherein the peptide of formula I′comprises at least two cysteine residues.
 58. The peptide orpharmaceutically acceptable salt thereof of claim 57, wherein thepeptide comprises two cysteine residues linked via a disulfide bond. 59.The peptide or pharmaceutically acceptable salt thereof of claim 57,wherein the peptide is PEGylated on R1′, X′, or Y′.
 60. The peptide orpharmaceutically acceptable salt thereof of claim 57, wherein a sidechain of an amino acid of the peptide is conjugated to a lipophilicsubstituent or a polymeric moiety.
 61. The peptide or pharmaceuticallyacceptable salt thereof according to claim 57, wherein R1′ is hydrogen,isovaleric acid, isobutyric acid or acetyl.
 62. The peptide orpharmaceutically acceptable salt thereof according to claim 57, whereinX′ is a peptide sequence having formula Ib′X1-Thr-His-X4-X5-X6-X7-X8-Phe-X10   (Ib′) (SEQ ID NO:14) wherein X1 isAsp, Ida, pGlu, bhAsp or absent; X4 is Phe or Dpa; X5 is Pro or bhPro;X6 is Ile, Cys or Arg; X7 is Cys, Ile, Leu or Val; X8 is Ile, Lys, Glu,Phe, Gln or Arg; and X10 is Lys or absent.
 63. The peptide orpharmaceutically acceptable salt thereof according to claim 57, whereinX′ is a peptide sequence having formula Ic′X1-Thr-His-X4-X5-Cys-Ile-X8-Phe-X10   (Ic′) (SEQ ID NO:15) wherein X1 isAsp, Ida, pGlu, bhAsp or absent; X4 is Phe or Dpa; X5 is Pro or bhPro;X8 is Ile, Lys, Glu, Phe, Gln or Arg; and X10 is Lys or absent.
 64. Thepeptide or pharmaceutically acceptable salt thereof according to claim63, wherein X1 is Asp, X4 is Phe, and X5 is Pro.
 65. The peptide orpharmaceutically acceptable salt thereof of claim 57, wherein thepeptide comprises one of the following sequences: (SEQ ID NO: 29)DTHFPICIFGPRSKGWVC; (SEQ ID NO: 38) DTHFPCIIFGPRSKGWVCK; (SEQ ID NO:128) DTHFPCIIFEPRSKGWVCK; (SEQ ID NO: 164) DTHFPCIIFGPRSKGWACK; (SEQ IDNO: 168) DTHFPCIIFGPRSKGWVCKK; (SEQ ID NO: 57 DTHFPCIIFVCHRPKGCYRRVCR;(SEQ ID NO: 125) DTHFPCIKFGPRSKGWVCK; (SEQ ID NO: 173)DTHFPCIKFKPRSKGWVCK; (SEQ ID NO: 106) DTHFPCIIFGPRSRGWVCK; (SEQ ID NO:135) DTHFPCIKFGPKSKGWVCK; (SEQ ID NO: 207) DTHFPCIKFEPRSKGCK; (SEQ IDNO: 265) DTHFPCIKFEPKSKGWECK; (SEQ ID NO: 245) DTHFPCIKFEPRSKKCK; (SEQID NO: 247) DTHFPCIKFEPRSKGCKK; (SEQ ID NO: 249) DTHFPCIKFKPRSKGCK; or(SEQ ID NO: 250) DTHFPCIKFEPKSKGCK.


66. The peptide or pharmaceutically acceptable salt thereof of claim 65,comprising one of the following structures: (SEQ ID NO: 29) Isovalericacid-DTHFPICIFGPRSKGWVC-NH₂; (SEQ ID NO: 38) Isovalericacid-DTHFPCIIFGPRSKGWVCK-NH₂; (SEQ ID NO: 128) Isovalericacid-DTHFPCIIFEPRSKGWVCK-NH₂; (SEQ ID NO: 164) Isovalericacid-DTHFPCIIFGPRSKGWACK-NH₂; (SEQ ID NO: 168) Isovalericacid-DTHFPCIIFGPRSKGWVCKK-NH₂; (SEQ ID NO: 57) Isovalericacid-DTHFPCIIFVCHRPKGCYRRVCR-NH₂; (SEQ ID NO: 172) Isovalericacid-DTHFPCI(K(PEG8))FGPRSKGWVCK-NH₂; (SEQ ID NO: 173) Isovalericacid-DTHFPCIKF(K(PEG8))PRSKGWVCK-NH₂; (SEQ ID NO: 199) Isovalericacid-DTHFPICIFGPRS(K(PEG8))GWVC-NH₂; (SEQ ID NO: 200) Isovalericacid-DTHFPICIFGPRS(K(PEG4))GWVC-NH₂; (SEQ ID NO: 201) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG8))-NH₂; (SEQ ID NO: 202) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG4))-NH₂; (SEQ ID NO: 203) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG2))-NH₂; (SEQ ID NO: 183) Isovalericacid-DTHFPCI(K(Palm))FGPRSKGWVCK-NH₂; (SEQ ID NO: 217) Isovalericacid-DTHFPCIKF)K(Palm))PRSKGWVCK-NH₂; (SEQ ID NO: 219) Isovalericacid-DTHFPCIKFGP(K(Palm))SKGWVCK-NH₂; (SEQ ID NO: 220) Isovalericacid-DTHFPCIKFGPRS(K(Palm))GWVCK-NH₂; (SEQ ID NO: 221) Isovalericacid-DTHFPCIKFGPRSKGWVC(K(Palm))NH₂; (SEQ ID NO: 222) Isovalericacid-DTHFPCI(K(PEG3-Palm))FGPRSKGWVCK- NH₂; (SEQ ID NO: 223) Isovalericacid-DTHFPCIKF(K(PEG3-Palm))PRSKGWVCK- NH₂; (SEQ ID NO: 224) Isovalericacid-DTHFPCIKFGP(K(PEG3-Palm))SKGWVCK- NH₂; (SEQ ID NO: 225) Isovalericacid-DTHFPCIKFGPRS(K(PEG3-Palm))GWVCK- NH₂; (SEQ ID NO: 226) Isovalericacid-DTHFPCIKFGPRSKGWVC(K(PEG3-Palm))- NH₂; (SEQ ID NO: 176) Isovalericacid-DTHFPCIKFGPRSKGWVC(K(PEG8))-NH₂; (SEQ ID NO: 241) Isovalericacid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK- NH₂; (SEQ ID NO: 242) Isovalericacid-DTHFPCIKF-K(isoGlu-Palm)-PRSKGCK- NH₂; (SEQ ID NO: 243) Isovalericacid-DTHFPCIKFEP(K(isoGlu-Palm))SKGCK- NH₂; (SEQ ID NO: 265) Isovalericacid- DTHFPCIKFEP(K(isoGlu-Palm))SKGWECK-NH₂; (SEQ ID NO: 244)Isovaleric acid- DTHFPCIKFEPRS(K(isoGlu-Palm))GCK-NH₂; (SEQ ID NO: 245)Isovaleric acid-DTHFPCIKFEPRSK(K(isoGlu-Palm))CK- NH₂; (SEQ ID NO: 246)Isovaleric acid-DTHFPCIKFEPRSKGCK(K(isoGlu-Palm))- NH₂; (SEQ ID NO: 248)Isovaleric acid-DTHFPCI-K(Dapa-Palm)-FEPRSKGCK- NH₂; (SEQ ID NO: 249)Isovaleric acid-DTHFPCIK(F(Dapa-Palm))PRSKGCK- NH₂; (SEQ ID NO: 250)Isovaleric acid-DTHFPCIKFEP(K(Dapa-Palm))SKGCK- NH₂; (SEQ ID NO: 251)Isovaleric acid-DTHFPCIKFEPRS(K(Dapa-Palm))GCK- NH₂; (SEQ ID NO: 252)Isovaleric acid-DTHFPCIKFEPRSK(K(Dapa-Palm))CK- NH₂; (SEQ ID NO: 253)Isovaleric acid-DTHFPCIKFEPRSKGC(K(Dapa-Palm))K- NH₂; or (SEQ ID NO:254) Isovaleric acid-DTHFPCIKFEPRSKGC(K(Dapa-Palm))- NH₂.


67. The peptide or pharmaceutically acceptable salt thereof of claim 66,wherein the peptide comprises two cysteine residues linked via adisulfide bond.
 68. A pharmaceutical composition comprising the peptideor pharmaceutically acceptable salt thereof of claim 57 and apharmaceutically acceptable carrier or excipient.
 69. The pharmaceuticalcomposition of claim 67, wherein the peptide or pharmaceuticallyacceptable salt thereof comprises one of the following sequences: (SEQID NO: 29) DTHFPICIFGPRSKGWVC; (SEQ ID NO: 38) DTHFPCIIFGPRSKGWVCK; (SEQID NO: 128) DTHFPCIIFEPRSKGWVCK; (SEQ ID NO: 164) DTHFPCIIFGPRSKGWACK;(SEQ ID NO: 168) DTHFPCIIFGPRSKGWVCKK; (SEQ ID NO: 57DTHFPCIIFVCHRPKGCYRRVCR; (SEQ ID NO: 125) DTHFPCIKFGPRSKGWVCK; (SEQ IDNO: 173) DTHFPCIKFKPRSKGWVCK; (SEQ ID NO: 106) DTHFPCIIFGPRSRGWVCK; (SEQID NO: 135) DTHFPCIKFGPKSKGWVCK; (SEQ ID NO: 207) DTHFPCIKFEPRSKGCK;(SEQ ID NO: 265) DTHFPCIKFEPKSKGWECK; (SEQ ID NO: 245)DTHFPCIKFEPRSKKCK; (SEQ ID NO: 247) DTHFPCIKFEPRSKGCKK; (SEQ ID NO: 249)DTHFPCIKFKPRSKGCK; or (SEQ ID NO: 250) DTHFPCIKFEPKSKGCK.


70. The pharmaceutical composition of claim 68, wherein the peptide orpharmaceutically acceptable salt thereof comprises one of the followingstructures: (SEQ ID NO: 29) Isovaleric acid-DTHFPICIFGPRSKGWVC-NH₂; (SEQID NO: 38) Isovaleric acid-DTHFPCIIFGPRSKGWVCK-NH₂; (SEQ ID NO: 128)Isovaleric acid-DTHFPCIIFEPRSKGWVCK-NH₂; (SEQ ID NO: 164) Isovalericacid-DTHFPCIIFGPRSKGWACK-NH₂; (SEQ ID NO: 168) Isovalericacid-DTHFPCIIFGPRSKGWVCKK-NH₂; (SEQ ID NO: 57) Isovalericacid-DTHFPCIIFVCHRPKGCYRRVCR-NH₂; (SEQ ID NO: 172) Isovalericacid-DTHFPCI(K(PEG8))FGPRSKGWVCK-NH₂; (SEQ ID NO: 173) Isovalericacid-DTHFPCIKF(K(PEG8))PRSKGWVCK-NH₂; (SEQ ID NO: 199) Isovalericacid-DTHFPICIFGPRS(K(PEG8))GWVC-NH₂; (SEQ ID NO: 200) Isovalericacid-DTHFPICIFGPRS(K(PEG4))GWVC-NH₂; (SEQ ID NO: 201) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG8))-NH₂; (SEQ ID NO: 202) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG4))-NH₂; (SEQ ID NO: 203) Isovalericacid-DTHFPCIIFGPRSRGWVC(K(PEG2))-NH₂; (SEQ ID NO: 183) Isovalericacid-DTHFPCI(K(Palm))FGPRSKGWVCK-NH₂; (SEQ ID NO: 217) Isovalericacid-DTHFPCIKF)K(Palm))PRSKGWVCK-NH₂; (SEQ ID NO: 219) Isovalericacid-DTHFPCIKFGP(K(Palm))SKGWVCK-NH₂; (SEQ ID NO: 220) Isovalericacid-DTHFPCIKFGPRS(K(Palm))GWVCK-NH₂; (SEQ ID NO: 221) Isovaleric acid-DTHFPCIKFGPRSKGWVC(K(Palm))NH₂; (SEQ ID NO: 222) Isovalericacid-DTHFPCI(K(PEG3-Palm))FGPRSKGWVCK- NH₂; (SEQ ID NO: 223) Isovalericacid-DTHFPCIKF(K(PEG3-Palm))PRSKGWVCK- NH₂; (SEQ ID NO: 224) Isovalericacid-DTHFPCIKFGP(K(PEG3-Palm))SKGWVCK- NH₂; (SEQ ID NO: 225) Isovalericacid-DTHFPCIKFGPRS(K(PEG3-Palm))GWVCK- NH₂; (SEQ ID NO: 226) Isovalericacid-DTHFPCIKFGPRSKGWVC(K(PEG3-Palm))- NH₂; (SEQ ID NO: 176) Isovalericacid-DTHFPCIKFGPRSKGWVC(K(PEG8))- NH₂; (SEQ ID NO: 241) Isovalericacid-DTHFPCI(K(isoGlu-Palm))FEPRSKGCK- NH₂; (SEQ ID NO: 242) Isovalericacid-DTHFPCIKF-K(isoGlu-Palm)-PRSKGCK- NH₂; (SEQ ID NO: 243) Isovalericacid-DTHFPCIKFEP(K(isoGlu-Palm))SKGCK- NH₂; (SEQ ID NO: 265) Isovalericacid-DTHFPCIKFEP(K(isoGlu- Palm))SKGWECK-NH₂; (SEQ ID NO: 244)Isovaleric acid-DTHFPCIKFEPRS(K(isoGlu-Palm))GCK- NH₂; (SEQ ID NO: 245)Isovaleric acid-DTHFPCIKFEPRSK(K(isoGlu-Palm))CK- NH₂; (SEQ ID NO: 246)Isovaleric acid-DTHFPCIKFEPRSKGCK(K(isoGlu-Palm))- NH₂; (SEQ ID NO: 248)Isovaleric acid-DTHFPCI-K(Dapa-Palm)-FEPRSKGCK- NH₂; (SEQ ID NO: 249)Isovaleric acid-DTHFPCIK(F(Dapa-Palm))PRSKGCK- NH₂; (SEQ ID NO: 250)Isovaleric acid-DTHFPCIKFEP(K(Dapa-Palm))SKGCK- NH₂; (SEQ ID NO: 251)Isovaleric acid-DTHFPCIKFEPRS(K(Dapa-Palm))GCK- NH₂; (SEQ ID NO: 252)Isovaleric acid-DTHFPCIKFEPRSK(K(Dapa-Palm))CK- NH₂; (SEQ ID NO: 253)Isovaleric acid-DTHFPCIKFEPRSKGC(K(Dapa-Palm))K- NH₂; or (SEQ ID NO:254) Isovaleric acid-DTHFPCIKFEPRSKGC(K(Dapa-Palm))- NH₂.


71. The pharmaceutical composition of claim 69, wherein the peptide orpharmaceutically acceptable salt thereof comprises two cysteine residueslinked via a disulfide bond.
 72. A method of treating a disease of ironmetabolism in a subject, comprising administering to the subject atleast one peptide or pharmaceutically acceptable salt thereof accordingto claim 57 or a pharmaceutical composition according to claim 67.